Document:

EX-10.26

 Exhibit 10.26 
 RESEARCH AGREEMENT 
 NO.
                 
 BY AND BETWEEN

 SURGIVISION, INC. 
 AND 
 THE UNIVERSITY OF UTAH 

This Research Agreement (“Agreement”) is entered into and effective as of
                                         
                   , by and between Surgi Vision, Inc, a Delaware corporation having a principal place of business at 200 N Cobb Parkway, Suite 140,
Marietta, Georgia 30062 (“Sponsor”) and the University of Utah, a body politic and corporate of the State of Utah (“University”). 
 RECITALS 
 WHEREAS, Sponsor wishes to fund research in MRI Guided EP
Ablation as outlined in this Agreement; and 
 WHEREAS, the performance of such research is consistent, compatible and
beneficial to the academic role and mission of University as an institution of higher education; and 
 WHEREAS, University is
qualified to provide such research. 
 AGREEMENT 
 NOW, THEREFORE, for and in consideration of the mutual covenants, conditions and undertakings herein set forth, the parties agree as follows: 
 1. Scope of Work. University agrees to perform certain research (“Research”) described in the Scope of Work set forth in Appendix A, which is attached hereto and incorporated herein by
this reference. 
 2. Period of Performance. The term of this Agreement shall be one-year, commencing on the effective date of this
Agreement. The Agreement shall automatically terminate one year from the effective date, unless both Sponsor and University agree in writing prior to the termination date, to extend the Agreement for a subsequent one-year renewal term subject to the
same terms and conditions stated herein. 
 3. Compensation and Payment. 

3.1 Compensation. Sponsor shall pay to University a total of $[***] USD (“Compensation”) in consideration for this
Agreement. The Compensation shall be used by the University substantially along the lines of the budget itemizing the costs of the Research, as set forth in Appendix B, which is attached hereto and incorporated herein by this reference. 

 

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 3.2 Payment. Sponsor shall pay an initial payment of $[***] of the Compensation
amount within 30 days of the effective date of this Agreement. Thereafter, monthly progress payments shall be made by Sponsor to University based upon monthly invoices submitted by University to Sponsor. The monthly invoices shall identify the
direct, facility and administrative costs. Invoices submitted to Sponsor shall be paid by Sponsor within thirty (30) days of receipt. Final payment shall include the unpaid balance of the Compensation and shall be paid upon completion of the
Research. Final payment of any remaining amount of Compensation unpaid at termination of the Agreement, if any, shall be made within 30 days of notification of completion of the Research. 
 Invoices shall be delivered to: 
 JOHN THOMAS 

200 N. COBB PARKWAY 
 MARIETTA, GA 30062 
 Compensation checks shall be payable to “The University of Utah”
and shall be sent to: 
 GARY S. GLEDHILL 
 UNIVERSITY OF UTAH 
 RESEARCH ACCOUNTING 

201 PRESIDENT’S CIRCLE, ROOM 406 
 SALT LAKE CITY UT 84112-9020 
 4. Technical Supervision. The person with primary
responsibility for supervision of the performance of the Research at the University shall be Dr. Nassir Marrouche. No other person shall replace or substitute for him in the supervisory responsibilities hereunder without the prior written
approval of Sponsor, which may be granted or withheld at Sponsor’s sole discretion, and with the consent of the University, which consent shall not be unreasonably withheld. 
 5. Reporting Requirements. University shall provide written reports to Sponsor on the progress of the performance of Research as outlined or required in the Scope of Work. A final written report
shall be furnished to Sponsor upon completion of the Research or within 60 days of the termination of the Agreement, whichever is earlier. 
 6.
Equipment. All equipment, instruments and materials purchased or used by University in connection with performance of the Research shall at all times remain under the control and ownership of University. This provision does not apply to
equipment, instruments or materials loaned to University by Sponsor, which shall remain the property of the Sponsor and shall be returned to Sponsor upon termination of this Agreement. 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

  
 2 

 7. Publication and Confidentiality. 

7.1 Publication. In furtherance of University’s role as a public institution of higher education, it is necessary that
significant results of research activities be reasonably available for publication by the University, and Sponsor acknowledges that University may publish the results of research conducted in connection with this Agreement. 

Notwithstanding the foregoing, University agrees that it shall not publish the results of research conducted in connection with this
Agreement, without the prior written consent of Sponsor, until the expiration of six (6) months following the first to occur of either the termination of this Agreement or submission of the final written report required under Section 4
hereof. In the event University wishes to publish research results prior to the expiration of the above described six (6) month period, University shall first provide to Sponsor written notice of University’s intent to publish and a draft
of such publication. Sponsor shall have thirty (30) days after receipt of the draft publication to request in writing the removal of portions deemed by Sponsor to contain confidential or patentable material owned by Sponsor, or to request a
delay in submission of the draft for publication pending Sponsor’s application for patent protection. In either event, University shall have no obligation to delay publication of the draft for longer than six (6) months following delivery
of University’s notice to Sponsor of intent to publish. If University does not receive Sponsor’s written response to the notice of intent to publish within the thirty (30) day period, then Sponsor shall be deemed to have consented to
such publication. However, information supplied to University by Sponsor and identified by Sponsor as proprietary information shall not be included in any material published by University without prior written consent of Sponsor. 

7.2 Confidentiality. Confidentiality. Sponsor acknowledges that University is a governmental entity and thus subject to the Utah
Governmental Records Access Management Act, Section 63-2-101 et seq., Utah Code Ann. (1997 and Supp 2005 as amended) (“GRAMA”) and Section 53B-16-301 et seq., Utah Code Ann. (1994 and Supp. 2005). Pursuant to GRAMA, a sponsor of
research may submit a single claim of business confidentiality concerning confidential business records exchanged during the research project. Thereafter, no party may obtain confidential business records from the University absent a court order
requiring the University to disclose the records. 
 8. Indemnification. 

8.1 Indemnification by University. It is understood that the Institution is a governmental entity and is subject to the
Governmental Immunity Act of Utah, Section 63-30d-101 et seq., Utah Code Ann. (2004, as amended) (“Act”). It is further understood that nothing in this Agreement shall be construed as a waiver of any rights or defenses applicable to
the Institution under the Act, including without limitation, the provisions of Section 63-30d-604 regarding limitation of judgments. Subject to the provisions of the Act, University agrees to indemnify, defend and hold harmless Sponsor, its
directors, officers, agents and employees against any actions, suits, proceedings, liabilities and damages that may result from the negligent acts or omissions of University, its officers, agents or employees in connection with this Agreement up to
the limits of the Utah Governmental Immunity Act. 

  
 3 

 8.2 Indemnification by Sponsor. Sponsor shall indemnify, defend and hold harmless

 University, its directors, officers, agents and employees against any actions, suits, proceedings, liabilities and damages
that may result from the negligent acts or omissions of Sponsor, its officers, agents or employees in connection with this Agreement. Sponsor shall not be responsible for any acts by employees, students or agents of University for Research carried
out under this Agreement. 
 8.3 Indemnification by University. University shall indemnify, defend and hold harmless
Sponsor, its directors, officers, agents and employees against any actions, suits, proceedings, liabilities and damages that may result from the negligent acts or omissions of University, its officers, agents or employees in connection with this
Agreement. 
 9. Compliance With Laws. In performance of the Research, Sponsor and University shall comply with all applicable federal,
state and local laws, codes, regulations, rules and orders. 
 10. Patents and Inventions. 

10.1 Background Intellectual Property. “Background Intellectual Property” means property and the legal right therein of
either or both parties developed before or independent of this Agreement, including inventions, patent applications, patents, copyrights, trademarks, mask works, trade secrets and any information embodying proprietary data such as technical data and
computer software. This Agreement does not grant and shall not be construed as implying that either party hereto shall have the right to use Background Intellectual Property of the other in connection with this Research except as otherwise provided
hereunder. 
 10.2 Notification of Inventions. Should any invention or improvement be developed during the course of the
Research, University shall notify Sponsor of such invention or improvement within thirty (30) days of knowledge of the invention or improvement. 
 10.3 Ownership. The University shall own all right, title and interest in all inventions and improvements conceived or reduced to practice solely by University or University personnel in the
performance of the Research (hereinafter collectively “University Invention”). Sponsor shall own all right, title and interest in all inventions and improvements conceived or reduced to practice by Sponsor, Sponsor personnel and/or
consultants thereof in the performance of the Research (hereinafter collectively “Sponsor Invention”). The University and Sponsor will jointly own all right title and interest in all inventions and improvements jointly conceived or reduced
to practice by inventors at the University and at Sponsor in the performance of the Research (hereinafter collectively “Joint Invention”). Inventorship shall be determined in accordance with U.S. Patent Law. 

10.4 Grant of Non-Exclusive License. In consideration of Sponsor’s support of the Research, University hereby grants to
Sponsor an irrevocable fully paid-up, non-royalty bearing, worldwide non-exclusive license with the right to sublicense, any patent, copyright or other intellectual property right associated with any University Invention, including the right to
practice the University Invention and the right to make, have made, use, import, offer for sale and sell products and processes covered by the University invention. 

  
 4 

 10.5 Option for Exclusive License. The University also grants to Sponsor a 6-month
Exclusive Option Period to any University Invention or to University’s interest in any Joint Invention, which option shall expire six (6) months after University has provided written notice to Sponsor of any such University Invention or
Joint Invention (“Option Period”). Upon exercise of the option in writing, the parties will meet within thirty (30) days to begin negotiating the terms of the license. The parties agree to negotiate in good faith. In the event an
exclusive license is not executed within six (6) months from the exercise of the option, or the option is not exercised within the Option Period, then subject to the non-exclusive license in 10.4, University shall be free to license the
University Invention or the University’s interest in any Joint Invention to others, at the University’s sole discretion with no further obligation to the Sponsor. In the event the University shall affirmatively decide to not pursue legal
protection of and/or abandon its rights to any such invention or improvement prior to exercise of said option, University shall timely notify Sponsor of this decision and assign to Sponsor all of the University’s rights, title and interest
therein. 
 11. Relationship of Parties. In assuming and performing the obligations of this Agreement, University and Sponsor are each
acting as independent parties and neither shall be considered or represent itself as a joint venturer, partner, agent or employee of the other. Neither party shall use the name or any trademark of the other party in any advertising, sales promotion
or other publicity matter without the prior written approval of the other party. University shall be responsible for determining what activities are appropriate under the Research and shall direct those activities. Sponsor shall not direct nor
determine what activities shall be carried out to perform the Research and shall not be held responsible for any activities carried out by researchers performing the Research at the University. 

12. Termination. This Agreement may be terminated by either party at any time, by giving written notice thereof to the other party. Such
termination shall be effective thirty (30) days after receipt of such notice. Termination shall not relieve either party of any obligation or liability accrued hereunder prior to such termination, or rescind or give rise to any right to rescind
any payments made prior to the time of such termination. 
 13. Uncontrollable Forces. Neither Sponsor nor University shall be considered
to be in default of this Agreement if delays in or failure of performance shall be due to uncontrollable forces the effect of which, by the exercise of reasonable diligence, the nonperforming party could not avoid. The term “uncontrollable
forces” shall mean any event which results in the prevention or delay of performance by a party of its obligations under this Agreement and which is beyond the control of the nonperforming party. It includes, but is not limited to, fire, flood,
earthquakes, storms, lightning, epidemic, war, riot, civil disturbance, sabotage, inability to procure permits, licenses, or authorizations from any state, local, or federal agency or person for any of the supplies, materials, accesses, or services
required to be provided by either Sponsor or University under this Agreement, strikes, work slowdowns or other labor disturbances, and judicial restraint. 
 14. Miscellaneous. 
 14.1 Assignment. University shall not assign or
transfer any interest in this Agreement, nor assign any claims for money due or to become due under this Agreement, without the prior written consent of the Sponsor. Sponsor shall have the right to assign this Agreement and the rights under 10.4 and
10.5, with prior written consent of University, and such consent shall not be unreasonably withheld. 

  
 5 

 14.2 Entire Agreement. This Agreement, with its attachments, constitutes the entire
agreement between the parties regarding the subject matter hereof and supersedes any other written or oral understanding of the parties. This Agreement may not be modified except by written instrument executed by both parties. 

14.3 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties, their successors and
permitted assigns. 
 14.4 Notices. Except as provided in Section 3 hereof regarding payment of invoices, any notice
or other communication required or permitted to be given to either party hereto shall be in writing and shall be deemed to have been received and properly given and effective: (a) on the date of delivery if delivered in person to an employee of
University or Sponsor during recipient’s normal business hours; or (b) on the date of delivery to the Notice Address if delivered by courier, express mail service or first-class mail, registered or certified, return receipt requested. Such
notice shall be sent or delivered to the respective addresses given below, or to such other address as either party shall designate by written notice given to the other party (Notice Address) as follows: 

In the case of University: 
  

					
	Technical	 		 	Contractual
			
	  	 		 	  
	Name: Dr. Marrouche	 		 	Brent Brown
	Title: Principal Investigator	 		 	UNIVERSITY OF UTAH
	Address: 30 N 1900 E, Rm 4A100	 		 	OFFICE OF SPONSORED PROJECTS
	Salt Lake City, UT 84132	 		 	 75 South 2000 East
 SALT
LAKE CITY UT 84112

 In the case of Sponsor: 
  

					
	Technical	 		 	Contractual
			
	  	 		 	  
	Name: Pete Piferi	 		 	Name: Kimble Jenkins
	Title: COO	 		 	Title: CEO
	Address: 50 N Front St.	 		 	Address: 50 N Front St.
	19th floor, Memphis TN 38103	 		 	19th floor, Memphis TN 38103

 Correspondence to be sent with a courtesy copy to: 
 Julie Richardson, Esq. 
 Myers Bigel Sibley & Sajovec, P.A. 

4140 Parklake Ave. 
 Raleigh, NC 27627 (Fax:
919-854-1401) 

  
 6 

 14.5 Order of Precedence. In the event of any conflict, inconsistency or discrepancy
amount, the Agreement and any other documents listed below shall be resolved by giving precedence in the following order. 
 (a)
This Agreement including the Exhibits hereto 
 (b) Purchase Order issued by Sponsor. In the event a purchase order is issued
under this Agreement and such purchase order contains standardized terms and conditions, the terms and conditions of this Agreement shall supercede and replace all such purchase order standardized terms and conditions. 

14.6 Governing Law and Disputes. This Agreement shall be interpreted and construed in accordance with the laws of the State of
Utah, without application of any principles of choice of laws. Disputes that cannot be resolved by Sponsor and University shall be determined by a court of competent jurisdiction in the State of Utah. 

14.7 Nonwaiver. A waiver by either party of any breach of this Agreement shall not be binding upon the waiving party unless such
waiver is in writing. In the event of a written waiver, such a waiver shall not affect the waiving party’s rights with respect to any other or further breach. 
 14.8 Use of Name. Sponsor may not use the name of University in any news release or advertising or any publications directed to the general public without written approval of University.

 14.9 Attorney Fees. The prevailing Party in any action or suit to enforce the terms or conditions of this Agreement
shall be entitled to recover its costs of court and reasonable attorneys’ fees incurred in enforcing the terms or conditions of this Agreement. 

  
 7 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly
authorized representatives effective as of the day and year first written above. 
  

									
	SURGIVISION, INC	 		 	UNIVERSITY OF UTAH
	    “Sponsor”	 		 	    “University”
					
	By:	 	/s/ Kimble Jenkins	 		 	By:	 	/s/ Brent K. Brown
		 	Signature	 		 		 	Signature
	Name:	 	Kimble Jenkins	 		 	Name:	 	Brent K. Brown
	Title:	 	President	 		 	Title:	 	Director, Office of Sponsored Projects
	Date:	 	7/2/07	 		 	Date:	 	6/22/07
			
	NASSIR MARROUCHE	 		 	
	“Primary Researcher”	 		 	
					
	Signature:	 	/s/ Nassir Marrouche	 		 		 	
					
	Title:	 	 	 		 		 	
					
	Date:	 	 	 		 		 	

  
 8 

 APPENDIX A 
 RESEARCH SCOPE OF WORK 
 [Insert Scope of Work referenced in Article 1.] 

  
 9 

 [***] 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

  
 10 

 APPENDIX B 
 RESEARCH AGREEMENT BUDGET 
 [Insert Budget referenced in Article 3.1] 

  
 12 

 [***] 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 13 

 FIRST AMENDMENT TO THE RESEARCH AGREEMENT 

BY AND BETWEEN 
 SURGIVISION, INC. 
 AND 

THE UNIVERSITY OF UTAH 
 This is a first Amendment to the Research Agreement (“Agreement”), by and between SurgiVision, Inc, a Delaware corporation having a principal place of business at 200 N Cobb Parkway, Suite 140,
Marietta, Georgia 30062 (“Sponsor”) and the University of Utah, a body politic and corporate of the State of Utah (“University”), executed by the Parties on July 2, 2007 and June 22, 2007, respectively. 

The enumerated provisions below replace the corresponding provisions in the original Agreement. All other provisions are unaffected by
this first Amendment. 
 NOW, THEREFORE, for and in consideration of the mutual covenants, conditions and undertakings set
forth, the parties agree to amend the Agreement as follows: 
 1. Scope of Work. University agrees to perform certain research
(“Research”) described in the Scope of Work set forth in Appendix A’, which is attached hereto and incorporated herein by this reference. 
 2. Period of Performance. The term of this Agreement shall be two-years, commencing on November 15, 2007, which shall be the new Effective Date of the Agreement. The Agreement shall
automatically terminate two years from the Effective Date, unless both Sponsor and University agree in writing, prior to the termination date, to extend the Agreement for a subsequent one or two-year renewal term subject to the same terms and
conditions stated herein, except that the monetary compensation may be altered if agreed to by both Sponsor and University in writing. 
 3.
Compensation and Payment. 
 3.1 Compensation. Sponsor shall pay to University a total of $[***] USD ($[***] under the
original Agreement and $[***] under this first Amendment) in year one (reduced by any prior payments made since execution of the original Agreement) and a total of $[***] in year two (“Compensation”) in consideration for this Agreement.
The Compensation shall be used by the University substantially along the lines of the budget itemizing the costs of the Research, as set forth in Appendix B’, which is attached hereto and incorporated herein by this reference. 

3.2 Payment. Sponsor shall remit quarterly progress payments to University based upon quarterly invoices submitted by University to
Sponsor. The invoices shall identify the direct, facility and administrative costs. Invoices submitted to Sponsor shall be paid each quarter by Sponsor within 30 days of receipt. Final payment shall include the unpaid balance of the Compensation and
shall be paid upon completion of the Research. Final payment of any remaining amount of Compensation unpaid at termination of the Agreement, if any, shall be made within 30 days of notification of completion of the Research. 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

  

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly
authorized representatives effective as of the day and year first written above. 
  

									
	SURGIVISION, INC	 		 	UNIVERSITY OF UTAH
	    “Sponsor”	 		 	    “University”
					
	By:	 	/s/ Kim Jenkins	 		 	By:	 	/s/ Brent K. Brown
		 	Signature	 		 		 	Signature
	Name:	 	Kim Jenkins	 		 	Name:	 	Brent K. Brown, Esq
		 	(Please print)	 		 		 	(Please print)
	Title:	 	CEO	 		 	Title:	 	Director, Office of Sponsored projects
	Date:	 	Nov 12, 2007	 		 	Date:	 	1/8/08
			
	NASSIR MARROUCHE	 		 	
	“Primary Researcher”	 		 	
					
	Signature:	 	/s/ Nassir Marrouche	 		 		 	
					
	Title:	 	 	 		 		 	
					
	Date:	 	 	 		 		 	

  
 2 

 APPENDIX A’ 
 RESEARCH SCOPE OF WORK 
 [***] 

 

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

  
 3 

 APPENDIX B’ 
 RESEARCH AGREEMENT BUDGET 
 See attached two sheets. 

  
 4 

 [***] 

 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 5 

 SECOND AMENDMENT TO THE RESEARCH AGREEMENT 

BY AND BETWEEN 
 SURGIVISION, INC. 
 AND 

THE UNIVERSITY OF UTAH 
 This is the second Amendment to the Research Agreement (as amended, the “Agreement”), by and between SurgiVision, Inc, a Delaware corporation having a principal place of business at One Commerce
Square, Suite 2550, Memphis, TN 38103 (“Sponsor”) and the University of Utah, a body politic and corporate of the State of Utah with a place of business at 75 South 2000 East, Rm. 211 RAB, Salt Lake City, UT 84112 (“University”),
executed by the Parties on July 2, 2007 and June 22, 2007, respectively. This Amendment has an effective date of April 24, 2009. 
 NOW, THEREFORE, for and in consideration of the mutual covenants, conditions and undertakings set forth, the Parties agree to amend the Agreement as follows: 

1. Section 3.1 Compensation. Sponsor shall pay to University a total of $[***] ($[***] under the original Agreement and previous Amendment)
in consideration for this Agreement. The Compensation shall be used by the University substantially along the lines of the budget itemizing the costs of the Research, as set forth in Appendix B, which is attached hereto and incorporated herein by
this reference. 
 All other terms and conditions of the Agreement shall remain in full force and effect and shall be unaffected
by this Second Amendment to the Research Agreement. 
 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed
by their duly authorized representatives effective as of the day and year first written above. 
  

									
	SURGIVISION, INC	 		 	UNIVERSITY OF UTAH
	    “Sponsor”	 		 	    “University”
					
	By:	 	/s/ Kim Jenkins	 		 	By:	 	/s/ Brent K. Brown
	Name:	 	Kim Jenkins	 		 	Name:	 	Brent K. Brown
	Title:	 	CEO	 		 	Title:	 	Director, Office of Sponsored Projects
	Date:	 	4/29/09	 		 	Date:	 	4/29/09
			
	NASSIR MARROUCHE	 		 	
	“Primary Researcher”	 		 	
					
	Signatures:	 	/s/ Nassir Marrouche	 		 		 	
	Date:	 	4/29/09	 		 		 	

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 THIRD AMENDMENT TO THE RESEARCH AGREEMENT 

BY AND BETWEEN 
 SURGIVISION, INC. 
 AND 

THE UNIVERSITY OF UTAH 
 This is the third Amendment to the Research Agreement (as amended, the “Agreement”), by and between SurgiVision, Inc., a Delaware corporation having a place of business at One Commerce Square,
Suite 2550, Memphis, TN 38103 (“Sponsor”), and the University of Utah, a body politic and corporate of the State of Utah with a place of business at 75 South 2000 East, Rm. 211, RAB, Salt Lake City, UT 84112 (“University”),
executed by the Parties on July 2, 2007 and June 22, 2007, respectively. This Amendment has an effective date of May 1, 2009. 
 NOW, THERFORE, for and in consideration of the mutual covenants, conditions and undertakings set forth, the Parties agree to amend the Agreement as follows: 

 

	 	1.	In addition to the funding described in Section 3.1 of the Agreement (which aggregate amount has already been paid by Sponsor to University), Sponsor shall provide
to University aggregate funding up to $[***] (the “Additional Funding”) with respect to the 4-month period of May, June, July, and August of 2009 (i.e., $[***] per month). Such Additional Funding shall be allocated and applied by
University (a) to carry out the Research under the Agreement, and (b) as outlined in the budget in Appendix A. 

  

	 	2.	University acknowledges that Sponsor has already paid University $[***] of the Additional Funding. Sponsor shall pay University the remaining balance of the Additional
Funding according to the following schedule: (a) Sponsor shall pay University $[***] following signature of this Amendment by both parties; and (b) Sponsor shall pay University the final $[***] on or before August 31, 2009.

  

	 	3.	University will provide Sponsor, on a timely basis, with information reasonably requested by Sponsor with respect to University’s actual allocation and application
of Additional Funding paid by Sponsor. 

 All other terms and conditions of the Agreement shall remain in full
force and effect and shall be unaffected by this Third Amendment to the Research Agreement. 
 IN WITNESS WHEREOF, the parties
have caused this Agreement to be executed by their duly authorized representatives effective as of the day and year first written above. 
  

									
	SURGIVISION, INC	 		 	UNIVERSITY OF UTAH
	    “Sponsor”	 		 	    “University”
					
	By:	 	 	 		 	By:	 	 
	Name:	 	Kim Jenkins	 		 	Name:	 	Brent K. Brown
	Title:	 	CEO	 		 	Title:	 	Director, Office of Sponsored

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 Appendix A 
 May-August 2009 Amended Budget for 
 SurgiVision/Siemens EP/MRI Collaboration
Project 
 [***] 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 2 

 FOURTH AMENDMENT TO THE RESEARCH AGREEMENT 

BY AND BETWEEN 
 SURGIVISION, INC. 
 AND 

THE UNIVERSITY OF UTAH 
 This is the Fourth Amendment to the Research Agreement (as previously amended, and as further amended by this Fourth Amendment, the “Research Agreement”), by and between SurgiVision,
Inc., a Delaware corporation having a place of business at One Commerce Square, Suite 2550, Memphis, TN 38103 (“Sponsor”), and the University of Utah, a body politic and corporate of the State of Utah with a place of business at 75
South 2000 East, Rm. 211, RAB, Salt Lake City, UT 84112 (“University”), executed by the Parties on July 2, 2007 and June 22, 2007, respectively. This Fourth Amendment is executed as of February 25, 2010, with an
effective date of September 1, 2009. 
 NOW, THERFORE, for and in consideration of the mutual covenants, conditions and
undertakings set forth, the parties agree to amend the Research Agreement as follows: 
 1. Defined Terms. Capitalized
terms used but not defined in this Fourth Amendment shall have the meanings ascribed to such terms in the Research Agreement. 

2. Extended Scope of Work. The term of the Research Agreement is extended through December 31, 2010. For the twelve
(12) month period commencing January 1, 2010 and ending December 31, 2010, University agrees to perform research activities described in or contemplated by the Scope of Work attached hereto as Exhibit A (the “SOW”)
for Sponsor’s exclusive benefit and to cooperate with Sponsor to facilitate a timely and successful completion of such research activities. For purposes of the Research Agreement, the term “Research” shall hereinafter include, without
limitation, research activities described in or contemplated by the SOW. University shall provide Sponsor the deliverables set forth in the SOW, on or before the dates set forth in the SOW. 

3. Additional SVI Support for Research. 
 (a) With respect to the four (4) month period commencing September 1, 2009 and ending December 31, 2009, Sponsor shall provide to University aggregate funding in the amount of [***], which
Sponsor shall pay in a single installment within thirty (30) days following the execution date of this Fourth Amendment. Such funding shall be allocated and applied by University (i) to carry out the Research for Sponsor’s exclusive
benefit, and (ii) to pay documented, reasonable and actual expenses in connection therewith. 
 (b) Provided
the Research Agreement is not earlier terminated, with respect to the twelve (12) month period commencing January 1, 2010 and ending December 31, 2010, Sponsor shall provide to University aggregate funding in an amount up to [***]
(the “Additional Funding”). The Additional Funding shall be allocated and applied by University (i) to carry out research activities described in or contemplated by the SOW for Sponsor’s exclusive benefit, and (ii) to
pay documented, reasonable and actual expenses in connection therewith, substantially in accordance with the itemized budget attached hereto as Exhibit B. Subject to the ultimate and penultimate sentences of this paragraph, and provided the Research
Agreement is 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

  

 
not earlier terminated, Sponsor shall pay to University the Additional Funding in four (4) payments according to the following schedule: (A) the first payment, in an amount no more than [***]
will be due and payable as of April 15, 2010; (B) the second payment, in an amount no more than [***] will be due and payable as of July 15, 2010; (C) the third payment, in an amount no more than [***] will be due and payable as of October 15, 2010;
and (D) the fourth payment, in an amount no more than [***] will be due and payable as of January 15, 2011. Notwithstanding the foregoing to the contrary, Sponsor’s obligation to make each payment of the Additional Funding is contingent upon
University’s compliance with the Research Agreement, including, but in no way limited to, the SOW. Sponsor reserves the right to suspend or withhold any payment of funds if University fails to comply strictly with the terms and conditions of
the Research Agreement (which, for the avoidance of any doubt, includes this Fourth Amendment), including, but in no way limited to, the failure by University to achieve the milestones, and/or the failure by University to provide Sponsor the
milestone deliverables, as set forth in the SOW. 
 (c) University shall continue to account for the funding
provided by Sponsor separately in University’s books and records, provided all such funding may be accounted for in a single University project account. A systematic accounting record shall be kept by University of the receipt and disbursement
of funds. University shall retain original substantiating documents related to specific expenditures and make these records available for Sponsor’s review upon request. University shall be responsible for maintaining adequate financial records
of the research program. Sponsor, or a designated representative, reserves the right, upon reasonable written notice, to audit University’s books and records relating to the expenditure of the Additional Funding. 

(d) University shall provide Sponsor, on a timely basis as reasonably requested by Sponsor, with written reports that
describe in reasonable detail University’s actual allocation and application of funding provided by Sponsor (e.g., salaries, supplies, etc.). 
 4. Amendment to Section 4 of the Research Agreement (Technical Supervision). Section 4 of the Research Agreement (Technical Supervision) is hereby amended by adding the following at the
end of such section: 
 “In the event Dr. Nassir Marrouche leaves University or otherwise withdraws from his role in
the performance of the Research, Sponsor may, in its sole discretion, terminate this Agreement or consent to University’s designation of a replacement or substitute.” 

5. Amendment to Section 5 of the Research Agreement (Reporting Requirements). Section 5 of the Research Agreement
(Reporting Requirements) is hereby amended by deleting the first sentence thereof in its entirety and substituting the following therefore: 
 “University shall provide periodic written reports to Sponsor as requested by Sponsor, which reports shall set forth in reasonable detail the status of the Research and the progress in the
performance of the Research to achieve any applicable objectives and/or milestones.” 
 6. Amendment to Section 7.1
of the Research Agreement (Publication). Section 7.1 of the Research Agreement (Publication) is hereby amended by deleting the second paragraph thereof in its entirety and substituting the following therefore: 

“Notwithstanding the foregoing, to protect the confidentiality of Confidential Information (as defined below) and/or the
patentability of inventions and improvements conceived or reduced to practice in the performance of the Research, University agrees (for itself and all of its personnel) to provide to Sponsor, for Sponsor’s review and comment, any proposed
publications or presentations which will disclose any findings, data or results of the research conducted in connection with this Agreement as soon as 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 2 

 
possible, but in any event at least thirty (30) days prior to submission of a manuscript or abstract for publication or to the date of the presentation. If Sponsor reasonably determines that
the proposed publication or presentation contains patentable subject matter which requires protection, or discloses any Confidential Information, University agrees (for itself and all of its personnel) (i) to delay publication or presentation
for a period of time, not to exceed sixty (60) days, for the purpose of filing one or more patent applications and/or (ii) to delete any Confidential Information therefrom, other than results created by the University and included in a
publication by a University student conducting research under this Agreement where such publication is required for the student’s academic advancement. If no written response is received from Sponsor within Sponsor’s review period, the
publication or presentation may proceed without delay. In the event University defaults in the performance of its duties and obligation under this paragraph, Sponsor shall have the right (but not the obligation) to terminate this Agreement
immediately upon written notice to University.” 
 7. Amendment to Section 7.2 of the Research Agreement
(Confidentiality). Section 7.2 of the Research Agreement (Confidentiality) is hereby amended by deleting such section in its entirety and substituting the following therefore (provided these changes shall not apply retroactively from the
date of execution of this Amendment): 
 “7.2 Confidentiality. 

(a) During the term of this Agreement, (i) Sponsor may provide University with confidential information for use by
University personnel in carrying out the research activities under this Agreement and (ii) in the course of carrying out the research activities under this Agreement, University personnel may develop confidential information for the Company
(such information described in clauses (i) and (ii), the “Confidential Information”). Subject to the provisions of paragraph (b) below, University agrees (for itself and for all University personnel who will be using or
developing Confidential Information): 
 (1) to hold Confidential Information in strict confidence and not to
disclose Confidential Information to anyone other than University personnel working on research activities under this Agreement who have a need to know this information and who are obligated to comply with restrictions contained herein, except as
expressly provided in clause (ii) of the second paragraph of Section 7.1; 
 (2) to refrain from copying,
distributing, disclosing, or summarizing Confidential Information, except to University personnel identified in clause (i) above, or except as expressly provided in clause (ii) of the second paragraph of Section 7.1; 

(3) to treat Confidential Information with at least the same degree of care that University uses to protect the
confidentiality of its own most commercially sensitive information; 
 (4) to advise all University personnel to
whom Confidential Information is disclosed that Confidential Information is highly confidential and subject to stringent conditions of confidentiality, and that Confidential Information may not be disclosed to third parties, posted in whole or part
on the Internet, disclosed in publications or presentations, or otherwise handled or used in contravention of the terms of this Agreement; 
 (5) to use Confidential Information only in connection with Research performed under this Agreement, and to cease use of Confidential Information upon any termination of this Agreement (for whatever
reason); and 
 (6) to return Confidential Information to Sponsor upon termination of this Agreement (for
whatever reason), and to retain only one copy (which includes any copy stored in computer memory) provided that University may retain one copy (which includes any copy stored in computer memory) solely for archival purposes in order to determine
University’s obligations hereunder. 

  
 3 

 The foregoing restrictions contained in this Section 7.2 shall not apply to any
information that (i) is already in the public domain or becomes available to the public through no breach of this Agreement; (ii) was lawfully in the possession of University prior to receipt from Sponsor, without an obligation of
confidentiality; (iii) is received by University independently from a third party free to lawfully disclose such information to University; or (iv) is subsequently independently developed by University, outside the scope of the research
activities under this Agreement and without use of the Confidential Information, as evidenced by University’s written records. Furthermore, if University is ordered to disclose any Confidential Information by a court or other governmental
entity having jurisdiction, University may disclose such Confidential Information, provided that University (A) gives Sponsor prompt written notice of the order so Sponsor can seek a protective order or similar relief and (B) reasonably
cooperates with Sponsor in protecting the confidential or proprietary nature of the Confidential Information required to be so disclosed. Except for the limited rights of use granted herein, nothing in this Agreement gives University or University
personnel any rights, title, license or interest whatsoever in any Confidential Information. All ownership and other rights therein are vested in and shall remain with Sponsor. 

(b) Sponsor acknowledges that University is a governmental entity subject to the Government Records Access and Management
Act, Utah Code §§ 63G-2-101 to -901, as amended, and Utah Code §§ 53B-16-301 through 53B-16-305, as amended (“Records Statutes”). As such, University’s confidentiality obligations under this Agreement shall be
subject in all respects to University’s compliance with Records Statutes. Pursuant to §§ 53B-16-304 and 63G-2-309 of the Utah Code, as amended, Sponsor hereby claims that the records it provides to University in connection with this
Agreement are confidential and protected against disclosure under Utah Code §§ 53B-16-302 and 63G-2-305, as amended, as such records relate to Sponsor’s proprietary research and development efforts. Accordingly, in the event that
University receives a request, pursuant to the Records Statutes, for records related to this Agreement, University shall be foreclosed, absent a court order or consent or acquiescence from Sponsor, from making the requested
disclosure. Notwithstanding the foregoing, in the event that University receives a request for records related to this Agreement, University shall, if deemed necessary by University’s legal counsel, release a general description of the
research conducted under this Agreement, excluding proprietary or competitive information, consistent with the provisions of §§ 53B-16-302 of the Utah Code, as amended. University shall promptly notify Sponsor in writing of any request it
receives for records related to this Agreement. 
 8. Amendment to Section 10.3 of the Research Agreement
(Ownership). Section 10.3 of the Research Agreement (Ownership) is hereby amended by deleting such section in its entirety and substituting the following therefore: 

“10.3 Ownership. The University shall own all right, title and interest in all inventions and improvements
conceived or reduced to practice, and all copyrightable materials created, solely by University or University personnel in the performance of the Research (hereinafter collectively “University Invention”). Sponsor shall own all right,
title and interest in all inventions and improvements conceived or reduced to practice, and all copyrightable materials created, by Sponsor, Sponsor personnel and/or consultants thereof in the performance of the Research (hereinafter collectively
“Sponsor Invention”). The University and Sponsor will jointly own all right, title and interest in all inventions and improvements jointly conceived or reduced to practice, and all copyrightable materials created, by personnel at the
University and at Sponsor in the performance of the Research (hereinafter collectively “Joint Invention”). Inventorship shall be determined in accordance with U.S. Patent Law.” 

  
 4 

 9. Amendment to Section 12 of the Research Agreement (Termination).
Section 12 of the Research Agreement (Termination) is hereby amended by deleting such section in its entirety and substituting the following therefore: 
 “12. Termination. 
 12.1 Term. Unless earlier
terminated as provided below, the term of this Agreement shall continue through December 31, 2010. 
 12.2
Default. If either Sponsor or University materially defaults in the performance of any duty or obligation imposed upon it by this Agreement and such default continues for thirty (30) days after written notice thereof has been given to
the defaulting party by the other party, such other party may (but need not) give notice of the immediate termination of this Agreement. Notwithstanding the foregoing to the contrary, Sponsor may terminate this Agreement immediately upon notice to
University in the event University defaults in the performance of its duties and obligations under Section 7.1 or Section 7.2 of this Agreement. 
 12.3 Primary Researcher. Sponsor shall have the right (but not the obligation) to terminate this Agreement upon written notice to University under the circumstances set forth in Section 4
hereof. 
 12.4 Return of Confidential Information. Upon termination of this Agreement for any reason,
University must promptly return to Sponsor all of Sponsor’s Confidential Information then in the possession or under the control of University and/or any of its personnel, provided that University may retain one copy (which includes any copy
stored in computer memory) of the Confidential Information for archival purposes in order to determine University’s obligations hereunder. 
 10. Amendment to Section 14 of the Research Agreement (Miscellaneous). Section 14 of the Research Agreement (Miscellaneous) is hereby amended by adding the following Section 14.10:

 “14.10 Research Involving Animals. With respect to any research activities covered by this
Agreement involving animal subjects, University agrees to comply with all applicable laws, rules and regulations of any governmental authority, agency or entity having jurisdiction over the research (including, but not limited to, the 1966 Federal
Animal Welfare Act and the 1985 Improved Standards of Laboratory Animals Acts.) This compliance includes, but is not limited to, the need for review and approval of University’s animal research/procedures for animal care by the appropriate
local Institutional Animal Care and Use Committee (IACUC). If such approval is required, University must provide a copy of this approval to Sponsor.” 
 11. Amendment to Section 14 of the Research Agreement (Miscellaneous). Section 14 of the Research Agreement (Miscellaneous) is hereby amended by adding the following Section 14.11:

 “14.11 Prohibition on Practice of Medicine. Notwithstanding anything to the contrary contained in
this Agreement, the parties acknowledge that Sponsor is not authorized or qualified to engage in any activity which may be construed or deemed to constitute the practice of medicine. Accordingly, University shall retain the authority to direct all
medical decisions regarding the care and treatment of its 

  
 5 

 
patients and shall assume full responsibility for any clinical decisions made as a result of data, directly or indirectly, generated during the research activities conducted. Sponsor shall
neither exercise control over nor interfere with the physician-patient relationship. To the extent any act or service required of Sponsor under this Agreement should be construed or deemed by a governmental authority, agency or court to constitute
the practice of medicine, the performance of said act or service by Sponsor shall be deemed waived and forever unenforceable.” 
 12. Amendment to Section 14 of the Research Agreement (Miscellaneous). Section 14 of the Research Agreement (Miscellaneous) is hereby amended by adding the following Section 14.12:

 “14.12 Anti-Kickback Statute. In compliance with the federal Medicare/Medicaid Anti-Kickback
Statute, each party represents that the funding to University has not been determined with regard to any implicit or explicit agreement to provide favorable procurement decisions with regard to Sponsor’s products or product candidates, and have
not been given in exchange for such decisions. Each party further represents that such compensation has not been determined with regard to the value or volume of any business generated between the parties and that such compensation is consistent
with fair market value in arm’s length transactions. The compensation provided hereunder is directly related to the costs of carrying out research, and includes no incentive payment to any individual for identifying or recruiting human
subjects. This Agreement is not intended to, and does not, induce the referral of patients or to induce purchase of any items or services reimbursed by any federal or state health care program.” 

13. Amendment to Section 14 of the Research Agreement (Miscellaneous). Section 14 of the Research Agreement
(Miscellaneous) is hereby amended by adding the following Section 14.13: 
 “14.13 Survival. The
provisions of Section 7 (Publication and Confidentiality), Section 8 (Indemnification), Section 10 (Patents and Inventions) Section 12.4 (Return of Confidential Information), and Section 14 (Miscellaneous) of this Agreement
(including subsections) will survive any termination of this Agreement.” 
 14. Change of Address. Notices and other
communications given to Sponsor under Section 14.4 (Notices) of the Research Agreement shall be sent or delivered to the addresses set forth below, or to such other address(es) as Sponsor shall designate by written notice given to University:

  

			
	Technical	  	Contractual
		
	Pete Piferi	  	Kimble Jenkins
	COO	  	CEO
	5 Musik	  	One Commerce Square, Ste. 2550
	Irvine, CA 92618	  	Memphis, TN 38103

 In each case with a courtesy copy to: 
 Oscar Thomas 
 VP, Business Affairs 
 One Commerce Square, Ste. 2550 
 Memphis, TN 38103 

  
 6 

 15. Exhibits. The Exhibits attached to this Fourth Amendment are hereby incorporated
into and made a part of this Fourth Amendment. 
 16. Ratification and Confirmation of Research Agreement. The parties
each acknowledge and agree that the Research Agreement is in full force and effect and has been in full force and effect at all times since its execution. The terms and provisions of the Research Agreement, as modified by the terms of this Fourth
Amendment, are hereby ratified and confirmed in all respects. 
 [The next page is the signature page] 

***** 

  
 7 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly
authorized representatives. 
  

									
	SURGIVISION, INC.	 		 	UNIVERSITY OF UTAH
	    “Sponsor”	 		 	    “University”
					
	By:	 	/s/ Kimble L. Jenkins	 		 	By:	 	/s/ Brent K. Brown
	Name:	 	Kimble L. Jenkins	 		 	Name:	 	Brent K. Brown
	Title:	 	CEO	 		 	Title:	 	Director, Office of Sponsored Projects

  
 8 

 Exhibit A 
 Scope of Work 
 Introduction: 

MRI-guided EP represents a promising new area for catheter-based cardiac mapping and ablation. There is tremendous potential for a novel,
comprehensive approach based on the unique imaging capabilities of MRI to treat a variety of cardiac arrhythmias. This comprehensive approach would include staging, planning, ablation and evaluation. 

Atrial fibrillation (AF) is the most common form of cardiac arrhythmia. AF is a growing problem in modern societies and has enormous impacts on both the
short-term quality of life as well as long-term survival. Approximately 0.5 percent of people aged 50 to 59 experience atrial fibrillation, and of the population aged 80 to 89, 9 percent are afflicted with AF—and the prevalence in each age
bracket is increasing. While many with the condition go untreated, AF is associated with an almost two-fold increase in the risk of mortality. AF patients experience a dramatically increased rate of stroke; from 1.5 percent for those aged 50 to 59
years to 23.5 percent for those aged between 80 and 89, a risk that generally decreases with age among the normal population. Additionally, the treatment of AF represents a significant health care burden with the annual costs estimated around
$7 billion. 
 Therefore, restoring and maintaining normal cardiac rhythm remains one of the major goals in treating patients with AF. One
treatment modality is a combination of electric shock (cardioversion) to restore regular cardiac rhythm and initiation of antiarrhythmic drugs. However, only 40-60 percent of the AF population is maintained in regular rhythm one year after such
treatment. Also, the treatment itself may have serious adverse effects and patients usually will need to take drugs throughout the remainder of their lives. Nevertheless, clinical trials have shown that maintaining sinus rhythm without the use of
antiarrhythmic medication seems to be associated with increased survival. 
 The inadequacies of drug-based treatments for AF have long been a
major motivation for achieving a greater comprehensive understanding of the disease and its substrate and initiation, and finding a truly alternative approach to maintain sinus rhythm and suppress AF. Currently, AF ablations occur in a traditional
angiography suite, with limited, at best, visualization of ablation procedures, catheter tracking and lesion formation. We propose that clinicians who are able to utilize an interventional MRI setting for the treatment, evaluation, and AF ablation
procedures will have significantly improved visualization of lesions, catheter tracking, precise atrial scarring and most importantly, improved patient outcomes. 

  
 9 

 Specific Aims of the Project: 
 MRI-guided, catheter-based cardiac EP procedures. This includes any pre-, intra- and post-procedure planning, ablation and/or evaluation directly associated with or necessary for the MRI-guided
procedure. However, it does not include diagnostic, assessment and triage activity not directly associated with the MRI-guided procedure, such as staging the progression of atrial disease, diagnostic devices and services to assist healthcare
professionals and patients evaluate treatment options. 
 As previously mentioned, atrial fibrillation (AF) is an electrophysiological
condition that represents an increasing problem in the aging populations of the world; AF significantly increases the risk of stroke and mortality and diminishes quality of life. The best current method to treat AF is the successful radio-frequency
(RF) ablation of cardiac tissue that may be causing the arrhythmia under the use of fluoroscopy. We propose to develop a MRI-compatible RF ablation catheter for use in a real-time MRI setting. The new catheters and techniques would replace the
traditional fluoroscopy method and theoretically provide better patient outcomes and more accurate ablation techniques. 
 Our recent findings
indicate that the MRI methods we have developed may provide a means to evaluate clinically relevant characteristics of lesion formation following RF ablation, specifically which tissue is actual scarring versus edema. This is only identifiable under
MRI evaluation. Perhaps even more than with other forms of cardiac arrhythmia, the substrate of the atrial tissue plays a key role in the occurrence of the condition. For example, there is a known but incompletely understood relationship between the
extent of fibrotic areas in the left atrium (LA) and the propensity for AF. 
 Listed below are the objectives for the project for the period
January 1, 2010 through December 31, 2010: 
 Project Objectives: 

 

	 	1.	Development and optimization of MRI sequences for best possible imaging of cardiac lesions.* 

* University will submit a detailed plan with respect to this objective to Sponsor for its approval (which will not be unreasonably
withheld or delayed), in order to avoid overlap and duplication of effort with the work being performed by Siemens. 
  

	 	2.	Characterization of cardiac MR lesion images described in Objective #1 by: 

 a. Comparing MR image data to histology (in animals); 
 b. Comparing MR image data
to electroanatomical map information (in animals and humans); 
 c. Comparing MR image data to outcome (humans, lesions created
in conventional EP suite) 
 [***] 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 10 

	 	3.	Publication of study results related to the development and science of MRI-guided atrial fibrillation ablation procedures.*** 

 

	 	***	Subject to Sponsor’s prior review and comment pursuant to the terms of the Research Agreement. 

Project Timelines and Periods: 

Required Milestones and Deliverables – University must achieve, and University must prepare and submit to Sponsor documentation demonstrating (to
Sponsor’s reasonable satisfaction) the successful achievement of, the following milestones on or before the dates set forth below: 

March 31, 2010 Milestones 
  

	 	•	 	 Provide Sponsor University’s detailed plan with respect Objective #1 (see above), which plan must be approved by Sponsor

 [***] 
  

	 	•	 	 Have data interface specified and tailored for Sponsor’s (and Siemens’) needs for product development work 

 

	 	•	 	 Provide Sponsor a comprehensive written presentation that discusses University’s success during the period in characterizing cardiac MR lesion
images by comparing (a) MR image data to histology (in animals), (b) MR image data to electroanatomical map information (in animals and humans), and (c) MR image data to outcome (humans, lesions created in conventional EP suite). Such
presentation must contain, at a minimum, (i) an executive summary summarizing University’s success during the period in characterizing cardiac MR lesion images, (ii) a reasonably detailed discussion of the work performed by University
during the period to characterize cardiac MR lesion images, (iii) a reasonably detailed description of any changes implemented by University from prior periods, (iv) details of the MRI sequences and MRI protocols used by University, and
(v) images and other information to support University’s success in characterizing cardiac MR lesion images. 

  

	 	•	 	 Participate in a meeting with Sponsor (which meeting may be held telephonically) to discuss (i) the results set forth in the presentation provided
to Sponsor per the immediately preceding bullet, and (ii) changes, if any, Sponsor would like University to implement for the upcoming period. 

 June 30, 2010 Milestones 
 [***] 

 

	 	•	 	 Provide Sponsor a comprehensive written presentation that discusses University’s success during the period in characterizing cardiac MR lesion
images by comparing (a) MR image data to histology (in animals), (b) MR image data to electroanatomical map information (in animals and humans), and (c) MR image data to outcome (humans, lesions created in conventional EP suite). Such
presentation must contain, at a minimum, (i) an executive 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 11 

	 	 
summary summarizing University’s success during the period in characterizing cardiac MR lesion images, (ii) a reasonably detailed discussion of the work performed by University during
the period to characterize cardiac MR lesion images, (iii) a reasonably detailed description of any changes implemented by University from prior periods, (iv) details of the MRI sequences and MRI protocols used by University, and
(v) images and other information to support University’s success in characterizing cardiac MR lesion images. 

  

	 	•	 	 Participate in a meeting with Sponsor (which meeting may be held telephonically) to discuss (i) the results set forth in the presentation provided
to Sponsor per the immediately preceding bullet, and (ii) changes, if any, Sponsor would like University to implement for the upcoming period. 

 September 30, 2010 Milestones 
  

	 	•	 	 Repeatable visualization of lesion formation using improved sequences. 

[***] 
  

	 	•	 	 Provide Sponsor a comprehensive written presentation that discusses University’s success during the period in characterizing cardiac MR lesion
images by comparing (a) MR image data to histology (in animals), (b) MR image data to electroanatomical map information (in animals and humans), and (c) MR image data to outcome (humans, lesions created in conventional EP suite). Such
presentation must contain, at a minimum, (i) an executive summary summarizing University’s success during the period in characterizing cardiac MR lesion images, (ii) a reasonably detailed discussion of the work performed by University
during the period to characterize cardiac MR lesion images, (iii) a reasonably detailed description of any changes implemented by University from prior periods, (iv) details of the MRI sequences and MRI protocols used by University, and
(v) images and other information to support University’s success in characterizing cardiac MR lesion images. 

  

	 	•	 	 Participate in a meeting with Sponsor (which meeting may be held telephonically) to discuss (i) the results set forth in the presentation provided
to Sponsor per the immediately preceding bullet, and (ii) changes, if any, Sponsor would like University to implement for the upcoming period. 

 December 31, 2010 Milestones 
  

	 	•	 	 Complete testing and validation of real-time software and prototypes of catheters during animal and phantom studies 

[***] 
  

	 	•	 	 Select appropriate journals for publication of results** 

 ** Subject to the terms of the Research Agreement, including Section 7.1 thereof. 
  

	 	•	 	 Provide Sponsor a comprehensive written presentation that discusses University’s success during the period in characterizing cardiac MR lesion
images by comparing (a) MR image data to histology (in animals), (b) MR image data to electroanatomical map information (in animals and humans), and (c) MR image data to outcome (humans, lesions created in conventional EP suite). Such
presentation must contain, at a minimum, (i) an executive 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 12 

	 	 
summary summarizing University’s success during the period in characterizing cardiac MR lesion images, (ii) a reasonably detailed discussion of the work performed by University during
the period to characterize cardiac MR lesion images, (iii) a reasonably detailed description of any changes implemented by University from prior periods, (iv) details of the MRI sequences and MRI protocols used by University, and
(v) images and other information to support University’s success in characterizing cardiac MR lesion images. 

  

	 	•	 	 Participate in a meeting with Sponsor (which meeting may be held telephonically) to discuss (i) the results set forth in the presentation provided
to Sponsor per the immediately preceding bullet, and (ii) changes, if any, Sponsor would like University to implement for the upcoming period. 

 Animal Experiments: 
 University will conduct at least three (3) animal experiments per
month, unless Sponsor consents in writing to a lesser number of experiments for any particular month. University will provide the goals and objectives of each animal experiment to Sponsor, in writing at least one (1) day prior to the
experiment, for Sponsor’s review, comment and approval. Within two (2) days after each animal experiment, University will provide Sponsor a written summary that describes the experiment (including key observations and findings from the
experiment) and indicates whether the goals and a objectives of the experiment were achieved. 
 Clinicians, Scientists, and Researchers:

 In order to achieve the objectives and milestones set forth above, there are several researchers, scientists, and clinicians that will be
involved with the project. The individual’s general responsibilities related to the project are explained below: 
 [***] 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 13 

 Exhibit B 
 Budget 
 [See Attached] 

  
 14 

 [***] 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 15 

 FIFTH AMENDMENT TO THE RESEARCH AGREEMENT 

BY AND BETWEEN 
 SURGIVISION, INC. 
 AND 

THE UNIVERSITY OF UTAH 
 UNIVERSITY OF UTAH REFERENCE NUMBER 10004541 AMENDMENT 5 
 This is the
Fifth Amendment to the Research Agreement (as previously amended, and as further amended by this Fifth Amendment, the “Research Agreement”), by and between SurgiVision, Inc., a Delaware corporation having a place of business at One
Commerce Square, Suite 2550, Memphis, TN 38103 (“Sponsor”), and the University of Utah, a body politic and corporate of the State of Utah with a place of business at 75 South 2000 East, Rm. 211, RAB, Salt Lake City, UT 84112
(“University”), executed by the Parties on July 2, 2007 and June 22, 2007, respectively. This Fourth Amendment is executed as of December 31, 2010, with an effective date of January 1, 2011. 

NOW, THERFORE, for and in consideration of the mutual covenants, conditions and undertakings set forth, the parties agree to amend the
Research Agreement as follows: 
 1. Defined Terms. Capitalized terms used but not defined in this Fifth Amendment shall
have the meanings ascribed to such terms in the Research Agreement. 
 2. Extended Scope of Work. The term of the
Research Agreement is extended through December 31, 2011. For the twelve (12) month period commencing January 1, 2011 and ending December 31, 2011, University agrees to perform research activities described in or contemplated by
the Scope of Work attached hereto as Exhibit A (the “SOW”) for Sponsor’s exclusive benefit and to cooperate with Sponsor to facilitate a timely and successful completion of such research activities. For purposes of the Research
Agreement, the term “Research” shall hereinafter include, without limitation, research activities described in or contemplated by the SOW. University shall provide Sponsor the deliverables set forth in the SOW, on or before the dates set
forth in the SOW. 
 3. Additional SVI Support for Research 

 

	 	(a)	 Provided the Research Agreement is not earlier terminated, with respect to the twelve (12) month period commencing January 1, 2011 and ending
December 31, 2011, Sponsor shall provide to University aggregate funding in an amount up to [***] (the “Additional Funding”). Carry over of previously awarded funding is approved from the previous project periods to the new
project period. The Additional Funding shall be allocated and applied by University (i) to carry out research activities described in or contemplated by the SOW for Sponsor’s exclusive benefit, and (ii) to pay documented, reasonable
and actual expenses in connection therewith, substantially in accordance with the itemized budget attached hereto as Exhibit B. Subject to the ultimate and penultimate sentences of this paragraph, and provided the Research Agreement is not earlier
terminated, Sponsor shall pay to University the Additional Funding in four (4) payments according to 

  

	[***]  	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

	 	
the following schedule: (A) the first payment, in the amount of [***], will be due and payable as of April 15, 2011; (B) the second payment, in the amount of [***], will be due and
payable as of July 15, 2011; (C) the third payment, in the amount of [***], will be due and payable as of October 15, 2011; and (D) the fourth payment, in the amount of [***], will be due and payable as of January 15, 2012.
Notwithstanding the foregoing to the contrary, Sponsor’s obligation to make each payment of the Additional Funding is contingent upon University’s compliance with the Research Agreement, including, but in no way limited to, the SOW.
Sponsor reserves the right to suspend or withhold any payment of funds if University fails to comply strictly with the terms and conditions of the Research Agreement (which, for the avoidance of any doubt, includes this Fifth Amendment), including,
but in no way limited to, the failure by University to achieve the milestones, and/or the failure by University to provide Sponsor the milestone deliverables, as set forth in the SOW. 

 

	 	(b)	University shall continue to account for the funding provided by Sponsor separately in University’s books and records, provided all such funding may be accounted
for in a single University project account. A systematic accounting record shall be kept by University of the receipt and disbursement of funds. University shall retain original substantiating documents related to specific expenditures and make
these records available for Sponsor’s review upon request. University shall be responsible for maintaining adequate financial records of the research program. Sponsor, or a designated representative, reserves the right, upon reasonable written
notice, to audit University’s books and records relating to the expenditure of the Additional Funding. 

  

	 	(c)	University shall provide Sponsor, on a timely basis as reasonably requested by Sponsor, with written reports that describe in reasonable detail University’s actual
allocation and application of funding provided by Sponsor (e.g., salaries, supplies, etc.). 

 4. Amendment to
Section 12 of the Research Agreement (Termination). Section 12.1 of the Research Agreement (Term) is hereby amended by deleting such section in nits entirety and substituting the following therefor: 

“12.1 Term. Unless earlier terminated as provided below, the term of this Agreement shall continue through
December 31, 2011.” 
 5. Exhibits. The Exhibits attached to this Fifth Amendment are hereby incorporated into
and made a part of this Fifth Amendment. 
 6. Ratification and Confirmation of Research Agreement. The parties each
acknowledge and agree that the Research Agreement is in full force and effect and has been in full force and effect at all times since its execution. The terms and provisions of the Research Agreement, as modified by the terms of this Fifth
Amendment, are hereby ratified and confirmed in all respects. 

  

	[***]  	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly
authorized representatives. 
  

									
	SURGIVISION, INC.	 		 	UNIVERSITY OF UTAH
	“Sponsor”	 		 	“University”
					
	By:	 	/s/ Kimble Jenkins	 		 	By:	 	/s/ Brent Brown
	Name:	 	Kimble L. Jenkins	 		 	Name:	 	Brent K. Brown
	Title:	 	CEO	 		 	Title:	 	Director, Office of Sponsored

  

 Exhibit A 
 Scope of Work 
 Introduction: 

MRI-guided EP represents a promising new area for catheter-based cardiac mapping and ablation. There is tremendous potential for a novel, comprehensive
approach based on the unique imaging capabilities of MRI to treat a variety of cardiac arrhythmias. This comprehensive approach would include staging, planning, ablation and evaluation. 
 Atrial fibrillation (AF) is the most common form of cardiac arrhythmia. AF is a growing problem in modern societies and has enormous impacts on both the short-term quality of life as well as long-term
survival. Approximately 0.5 percent of people aged 50 to 59 experience atrial fibrillation, and of the population aged 80 to 89, 9 percent are afflicted with AF—and the prevalence in each age bracket is increasing. While many with the condition
go untreated, AF is associated with an almost two-fold increase in the risk of mortality. AF patients experience a dramatically increased rate of stroke; from 1.5 percent for those aged 50 to 59 years to 23.5 percent for those aged between 80 and
89, a risk that generally decreases with age among the normal population. Additionally, the treatment of AF represents a significant health care burden with the annual costs estimated around $7 billion. 

Therefore, restoring and maintaining normal cardiac rhythm remains one of the major goals in treating patients with AF. One treatment modality is a
combination of electric shock (cardioversion) to restore regular cardiac rhythm and initiation of antiarrhythmic drugs. However, only 40-60 percent of the AF population is maintained in regular rhythm one year after such treatment. Also, the
treatment itself may have serious adverse effects and patients usually will need to take drugs throughout the remainder of their lives. Nevertheless, clinical trials have shown that maintaining sinus rhythm without the use of antiarrhythmic
medication seems to be associated with increased survival. 
 The inadequacies of drug-based treatments for AF have long been a major motivation
for achieving a greater comprehensive understanding of the disease and its substrate and initiation, and finding a truly alternative approach to maintain sinus rhythm and suppress AF. Currently, AF ablations occur in a traditional angiography suite,
with limited, at best, visualization of ablation procedures, catheter tracking and lesion formation. We propose that clinicians who are able to utilize an interventional MRI setting for the treatment, evaluation, and AF ablation procedures will have
significantly improved visualization of lesions, catheter tracking, precise atrial scarring and most importantly, improved patient outcomes. 

  

 Specific Aims of the Project: 
 MRI-guided, catheter-based cardiac EP procedures. This includes any pre-, intra- and post-procedure planning, ablation and/or evaluation directly associated with or necessary for the MRI-guided
procedure. However, it does not include diagnostic, assessment and triage activity not directly associated with the MRI-guided procedure, such as staging the progression of atrial disease, diagnostic devices and services to assist healthcare
professionals and patients evaluate treatment options. 
 As previously mentioned, atrial fibrillation (AF) is an electrophysiological
condition that represents an increasing problem in the aging populations of the world; AF significantly increases the risk of stroke and mortality and diminishes quality of life. The best current method to treat AF is the successful radio-frequency
(RF) ablation of cardiac tissue that may be causing the arrhythmia under the use of fluoroscopy. 
 Our recent findings indicate that the MRI
methods we have developed may provide a means to evaluate clinically relevant characteristics of lesion formation following RF ablation, specifically which tissue is actual scarring versus edema. This is only identifiable under MRI evaluation.
Perhaps even more than with other forms of cardiac arrhythmia, the substrate of the atrial tissue plays a key role in the occurrence of the condition. For example, there is a known but incompletely understood relationship between the extent of
fibrotic areas in the left atrium (LA) and the propensity for AF. 
 Listed below are the objectives for the project for the period
January 1, 2011 through December 31, 2011: 
 Project Objectives: 

 

	1.	Development and optimization of MRI sequences for best possible imaging of cardiac lesion formation in the setting of real-time MRI (RT-MRI) guided ablation, which
includes (a) the ability to objectively visualize lesion formation under RT-MRI (i.e., the formation of the lesion can be prominently seen) and (b) the ability to visualize under RT-MRI every lesion that is formed (i.e., 100% of lesions
formed are seen).* 

  

	2.	Characterization of cardiac lesions through the development of MRI sequences and methods that will assess the extent of scarring intra-procedurally during the RT-MRI
guided ablation procedure, including (a) assessment of the size and transmurality of the lesions, and (b) characterization of a permanent scar versus edema or other temporary injury.* 

 

	3.	[***] 

  

	4.	Improvement of hardware and software for RT-MRI guided ablation system through testing and feedback from University. 

 

	5.	Establishment of the clinically relevant requirements of the RT-MRI guided ablation system, and development and optimization of the clinical workflow for a RT-MRI
guided ablation procedure. 

  

	6.	Progress towards first success in applying RT-MRI ablation to humans. 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

	7.	Publication of study results related to the development and science of RT-MRI guided atrial fibrillation ablation procedures.*** 

* Access to pulse sequence source code to be provided through separate research agreement with Siemens. 

[***] 
 *** Subject to Sponsor’s prior
review and comment pursuant to the terms of the Research Agreement and co-authorship as appropriate for Sponsor’s and/or Siemens’ personnel. 
 Project Timelines and Periods: 
 Required Milestones and Deliverables – University
must achieve, and University must prepare and submit to Sponsor documentation demonstrating (to Sponsor’s reasonable satisfaction) the successful achievement of, the following milestones on or before the dates set forth below: 

March 31, 2011 Milestones 
  

	 	•	 	 Prepare a written plan for University’s work to achieve Project Objective #1 above (Visualization Plan) and provide the plan to Sponsor for its
review and approval. University’s Visualization Plan should also discuss what support (software and/or hardware) is needed by University from Sponsor and/or Siemens in order for University to implement the plan. 

 

	 	•	 	 Prepare a written plan for University’s work to achieve Project Objective #2 above (Characterization Plan) and provide the plan to Sponsor for its
review and approval. University’s Characterization Plan should also discuss what support (software and/or hardware) is needed by University from Sponsor and/or Siemens in order for University to implement the plan.+ 

+ The Visualization Plan and the Characterization Plan could be combined into a single plan and provided to Sponsor for
its review and approval. 
  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 Compare performance (anatomical accuracy and quality of electrogram signals) of MR guided electroanatomical mapping with current clinical standards,
e.g., Biosense/Carto. 

  

	 	•	 	 Prepare first draft of IRB protocol for IDE application. 

 

	 	•	 	 Publish first journal article on MRI based electroanatomical mapping (EAM) system.* 

* Subject to the terms of the Research Agreement, including Section 7.1. 

 

	 	•	 	 Publish first journal article on MRI scar map guided ablation.* 

* Subject to the terms of the Research Agreement, including Section 7.1. 

 

	 	•	 	 [***] 

  

	 	•	 	 Test and evaluate hardware (i.e., devices/equipment) for RT-MRI guided ablation system, as requested by Sponsor, and provide feedback to Sponsor.

  

	 	•	 	 [***] 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

	 	•	 	 Demonstrate improvements in RT-MRI visualization of lesion formation. 

 

	 	•	 	 Demonstrate improvements in characterization of cardiac lesions. 

 

	 	•	 	 Provide Sponsor access to University clinicians to gain clinical feedback. 

 

	 	•	 	 Participate in weekly telephone conference meetings with Sponsor to evaluate progress, discuss approaches to overcoming technical hurdles, develop
plans for the coming experiments, and assign tasks for project participants. 

  

	 	•	 	 Prepare end-of-quarter report which discusses University’s progress during the period in achieving the Project Objectives and identifies the basis
upon which University believes it achieved the period milestones.** 

 ** Format of the report
to be discussed. 
 June 30, 2011 Milestones 
  

	 	•	 	 Prepare strategic plan to achieve first success in applying RT-MRI ablation to humans. 

 

	 	•	 	 Prepare initial detailed flow-chart for the clinical workflow of a RT-MRI guided ablation procedure. 

 

	 	•	 	 [***] 

  

	 	•	 	 Evaluate imaging of lesion formation through ablation under various power settings and durations in the right ventricle. 

 

	 	•	 	 Complete journal article on technical approaches for MRI guided scar mapping and EAM.* 

* Subject to the terms of the Research Agreement, including Section 7.1. 

 

	 	•	 	 Complete journal article on mapping of no reflow regions and correlation with 3-month scar mapping.* 

* Subject to the terms of the Research Agreement, including Section 7.1. 

 

	 	•	 	 Test and evaluate hardware (i.e., devices/equipment) for RT-MRI guided ablation system, as requested by Sponsor, and provide feedback to Sponsor.

  

	 	•	 	 [***] 

  

	 	•	 	 Demonstrate improvements in RT-MRI visualization of lesion formation. 

 

	 	•	 	 Demonstrate improvements in characterization of cardiac lesions. 

 

	 	•	 	 Perform the work set forth in the agreed-upon Visualization and Characterization Plans. 

 

	 	•	 	 Provide Sponsor access to University clinicians to gain clinical feedback. 

 

	 	•	 	 Participate in weekly telephone conference meetings with Sponsor to evaluate progress, discuss approaches to overcoming technical hurdles, develop
plans for the coming experiments, and assign tasks for project participants. 

  

	 	•	 	 Prepare end-of-quarter report which discusses University’s progress during the period in achieving the Project Objectives, documents
University’s efforts under the Visualization, Characterization and [***] Plans, and identifies the basis upon which University believes it achieved the period milestones. 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 September 30, 2011 Milestones 

 

	 	•	 	 Prepare revised detailed flow-chart for the clinical workflow of a RT-MRI guided ablation procedure. 

 

	 	•	 	 Submit application for first IDE meeting with FDA. 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 Complete journal article on use of statistical shape analysis for pre and post ablation LA shape.* 

* Subject to the terms of the Research Agreement, including Section 7.1. 

 

	 	•	 	 Test and evaluate hardware (i.e., devices/equipment) for RT-MRI guided ablation system, as requested by Sponsor, and provide feedback to Sponsor.

  

	 	•	 	 [***] 

  

	 	•	 	 Demonstrate improvements in RT-MRI visualization of lesion formation. 

 

	 	•	 	 Demonstrate improvements in characterization of cardiac lesions. 

 

	 	•	 	 Perform the work set forth in the agreed-upon Visualization and Characterization Plans. 

 

	 	•	 	 Provide Sponsor access to University clinicians to gain clinical feedback. 

 

	 	•	 	 Participate in weekly telephone conference meetings with Sponsor to evaluate progress, discuss approaches to overcoming technical hurdles, develop
plans for the coming experiments, and assign tasks for project participants. 

  

	 	•	 	 Prepare end-of-quarter report which discusses University’s progress during the period in achieving the Project Objectives, documents
University’s efforts under the Visualization, Characterization and [***] Plans, and identifies the basis upon which University believes it achieved the period milestones. 

December 31, 2011 Milestones 
  

	 	•	 	 Prepare final detailed flow-chart for the clinical workflow of a RT-MRI guided ablation procedure. 

 

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 Test and evaluate hardware (i.e., devices/equipment) for RT-MRI guided ablation system, as requested by Sponsor, and provide feedback to Sponsor.

  

	 	•	 	 [***] 

  

	 	•	 	 Demonstrate improvements in RT-MRI visualization of lesion formation. 

 

	 	•	 	 Demonstrate improvements in characterization of cardiac lesions. 

 

	 	•	 	 Perform the work set forth in the agreed-upon Visualization and Characterization Plans. 

 

	 	•	 	 Provide Sponsor access to University clinicians to gain clinical feedback. 

 

	 	•	 	 Participate in weekly telephone conference meetings with Sponsor to evaluate progress, discuss approaches to overcoming technical hurdles, develop
plans for the coming experiments, and assign tasks for project participants. 

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

	 	•	 	 Prepare end-of-quarter report which discusses University’s progress during the period in achieving the Project Objectives, documents
University’s efforts under the Visualization, Characterization and [***] Plans, and identifies the basis upon which University believes it achieved the period milestones. 

Roles of University Personnel: 
 [***]

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 Exhibit B 
 Budget 
 [See Attached] 

  

 [***] 

  

	[***]  	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 SIXTH AMENDMENT TO THE RESEARCH AGREEMENT 

BY AND BETWEEN 
 MRI INTERVENTIONS, INC 
 (FORMERLY SURGIVISION, INC.) 

AND 
 THE
UNIVERSITY OF UTAH 
 UNIVERSITY OF UTAH REFERENCE NUMBER 10004541 AMENDMENT 6 

This is the Sixth Amendment to the Research Agreement (as previously amended, and as further amended by this Sixth Amendment, the
“Research Agreement”), by and between MRI Interventions, Inc. (formerly SurgiVision, Inc.), a Delaware corporation having a place of business at One Commerce Square, Suite 2550, Memphis, TN 38103 (“Sponsor”), and
the University of Utah, a body politic and corporate of the State of Utah with a place of business at 75 South 2000 East, Rm. 211, RAB, Salt Lake City, UT 84112 (“University”), executed by the Parties on July 2, 2007 and June 22,
2007, respectively. This Sixth Amendment is executed as of 28 November 2011, with an effective date of 28 November 2011. 

Whereas all the terms and conditions agreed upon in the Research Agreement shall remain in full force and effect, and enforceable in
accordance with its terms, with the exception of the amendments provided herein. 
 NOW, THERFORE, for and in consideration of
the mutual covenants, conditions and undertakings set forth, the parties agree to amend the Research Agreement as follows: 

1.        Defined Terms. Capitalized terms used but not defined in this Sixth Amendment
shall have the meanings ascribed to such terms in the Research Agreement. 

2.        Extended Term. The term of the Research Agreement is extended through 31 March
2012. 
 IN WITNESS WHEREOF, the parties have caused this Sixth Amendment to be executed by their duly authorized
representatives. 
  

													
		 	 SURGIVISION, INC.
           “Sponsor”
	 		 	 UNIVERSITY OF UTAH
           “University”
	 	
							
		 	By:	 	   /s/ Kimble L. Jenkins
	 		 	By:	 	   /s/ Todd B. Nilsen
	 	
		 	Name: Kimble L. Jenkins	 	Name: Todd B. Nilsen, J.D.	 	
		 	Title: CEO	 	Title: Associate Director	 	
		 		 		 		 	         Sponsored ProjectsEX-10.37

 Exhibit 10.37 
 AMENDMENT No. 1 
 to 

LOAN AGREEMENT, 
 SECURED CONVERTIBLE PROMISSORY NOTES, 
 and PATENT SECURITY AGREEMENT

 This AMENDMENT (this “Amendment”) is made as of this 2nd day of February, 2012, by and between
(i) MRI Interventions, Inc., a Delaware corporation formerly known as SurgiVision, Inc. (the “Company”), and (ii) Boston Scientific Corporation (“BSC”). Unless otherwise defined herein, capitalized terms
used herein shall have the respective meanings set forth in the Loan Agreement referred to below. 
 WHEREAS, the Company
and BSC entered into that certain Loan Agreement dated October 16, 2009 (the “Loan Agreement”); 

WHEREAS, the Company issued to BSC each of (i) that certain Secured Convertible Promissory Note, dated as of October 16,
2009, in the original principal amount of $2,000,000 (the “October 2009 Note”), (ii) that certain Secured Convertible Promissory Note, dated as of November 17, 2009, in the original principal amount of $750,000 (the
“November 2009 Note”), and (iii) that certain Secured Convertible Promissory Note, dated as of December 18, 2009, in the original principal amount of $750,000 (the “December 2009 Note”, and together with
the October 2009 Note and the November 2009 Note, the “Existing Notes”); 
 WHEREAS, the Company and BSC
entered into that certain Patent Security Agreement dated October 16, 2009 (the “Patent Security Agreement”); 
 WHEREAS, on the date hereof, Boston Scientific Neuromodulation Corporation and the Company are entering into the Omnibus Amendment No. 3 to System and Lead Development and Transfer Agreement
and Technology License Agreement (the “IP Amendment”); 
 WHEREAS, in consideration for the
Company’s agreements in the IP Amendment, the Company and BSC desire to modify certain provisions of the Loan Agreement, the Existing Notes, and the Patent Security Agreement; and 

 NOW, THEREFORE, in consideration of the foregoing and the mutual promises made
herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 I. AMENDMENTS TO LOAN AGREEMENT. 
 1.1. Amendment of
Section 3.2. Section 3.2 of the Loan Agreement is hereby amended in its entirety to read as follows: 
 “3.2 Interest. All overdue amounts payable hereunder or under the Notes or the Patent Security Agreement shall bear interest compounded annually and payable on demand at a rate equal to
10% per annum from the date such payment was due until such amount shall be paid in full (after as well as before judgment).” 
 1.2 Amendment of Section 3.4. Section 3.4 of the Loan Agreement is hereby amended to add the following new paragraph (f) at the end of such section: 

“(f) Covenant of the Company to file Certificate of Designation of Series B Preferred Stock. The Company
covenants and agrees that, within two (2) business days following delivery by BSC to the Company of notice of BSC’s election to convert the Notes into Series B Preferred Stock pursuant to Sections 3.4(a) or (b) above, the Company
shall file with the Secretary of State of Delaware a Certificate of Designation, Preferences and Rights with respect to the Series B Preferred Stock in a form to be mutually agreed to by the Company and BSC prior to the earlier of (i) the
conversion of the outstanding shares of Series A Preferred Stock into Common Stock or (ii) March 31, 2012.” 

1.3 Amendment of Section 6.2(j). Section 6.2(j) of the Loan Agreement is hereby amended in its entirety to read
as follows: 
 “(j) Indebtedness. Incur or guarantee any Indebtedness (other than to BSC and other
than as set forth on Schedule 6.2 hereto), repay any Indebtedness (including the principal amount of any Indebtedness and any accrued interest on any Indebtedness), or amend the terms of any Indebtedness of the Company (including pursuant to
Section 6.8);” 
 1.4 Amendment of Section 6. Section 6 of the Loan Agreement is hereby amended to
add the following new Section 6.8 at the end of Section 6: 
 “6.8 Existing Indebtedness.
The Company hereby covenants and agrees that as of or prior to the earlier of (x) February 28, 2012 or (y) the effective date of a registration statement filed by the Company with respect to the Company’s common stock under the
Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (such earlier date, the “Amendment Date”), either (i) the Company shall enter into amendments to each of the promissory notes listed on
Schedule 6.2 hereto (other than the November 2010 Notes), each of such amendments to be on terms satisfactory to BSC, pursuant to which as of or prior to the Amendment Date the maturity date of the Company’s Indebtedness under each of
such promissory notes is extended beyond December 18, 2014 and 

  
 2 

 
the Indebtedness of the Company under each of such promissory notes is subordinated to the Indebtedness of the Company to BSC under the Restated Notes on terms satisfactory to BSC, or
(ii) all Indebtedness of the Company under each of such promissory notes is converted in full into shares of Common Stock (or, in the case of the Brainlab Note, into Common Stock or Preferred Stock which is junior in right of payment to the
series of preferred stock of the Company into which the Restated Notes are convertible and which otherwise has terms satisfactory to BSC) on or prior to the Amendment Date and such promissory notes shall no longer be outstanding as of the Amendment
Date.” 
 1.5 Amendment of Definition of “Loans”. The Company and BSC hereby agree that all amounts
owing by the Company to BSC under the Restated Notes (as defined herein) shall be deemed to be Loans under the Loan Agreement and all references in the Loan Agreement to the Loans shall be deemed to refer to the obligations of the Company under the
Restated Notes. 
 1.6 Amendment of Definition of “Notes”. The Company and BSC hereby agree that the
Restated Notes shall be deemed to be Notes under the Loan Agreement and all references in the Loan Agreement to the Notes shall be deemed to refer to the Restated Notes. 
 1.7 Amendment of Definition of “Series B Preferred Stock”. 
 ““Series B Preferred Stock” means a series of Preferred Stock of the Company which is pari passu with the Series A Preferred Stock and senior to all other shares of preferred stock
of the Company, and which has the terms agreed to by the Company and BSC pursuant to Section 3.4(f).” 
 1.8
Amendment to Schedules to Loan Agreement. The Company and BSC hereby agree that the Loan Agreement is amended to add a new Schedule 6.2 thereto in the form of Schedule 6.2 attached hereto. 

II. AMENDMENT AND RESTATEMENT OF THE EXISTING NOTES. 

2.1 October 2009 Note. The Company and BSC agree that the accrued and unpaid interest on the October 2009 Note as of
the date hereof is equal to $2,492,931.51. The Company and BSC agree that all accrued interest on the October 2009 Note as of the date hereof shall be added to the principal amount of the October 2009 Note as of the date hereof. The Company shall
execute and deliver to BSC on the date hereof an Amended and Restated Secured Convertible Promissory Note in the form of Exhibit A hereto (the “Restated October 2009 Note”). Upon the Company’s execution and delivery to
BSC of the Restated October 2009 Note, BSC shall surrender the October 2009 Note to the Company for cancellation. 

  
 3 

 2.2 November 2009 Note. The Company and BSC agree that the accrued and
unpaid interest on the November 2009 Note as of the date hereof is equal to $926,893.15. The Company and BSC agree that all accrued interest on the November 2009 Note as of the date hereof shall be added to the principal amount of the November 2009
Note as of the date hereof. The Company shall execute and deliver to BSC on the date hereof an Amended and Restated Secured Convertible Promissory Note in the form of Exhibit B hereto (the “Restated November 2009 Note”). Upon
the Company’s execution and delivery to BSC of the Restated November 2009 Note, BSC shall surrender the November 2009 Note to the Company for cancellation. 
 2.3 December 2009 Note. The Company and BSC agree that the accrued and unpaid interest on the December 2009 Note as of the date hereof is equal to $918,776.58. The Company and BSC agree
that all accrued interest on the December 2009 Note as of the date hereof shall be added to the principal amount of the December 2009 Note as of the date hereof. The Company shall execute and deliver to BSC on the date hereof an Amended and Restated
Secured Convertible Promissory Note in the form of Exhibit C hereto (the “Restated December 2009 Note”, and together with the Restated October 2009 Note and the Restated November 2009 Note, the “Restated
Notes”). Upon the Company’s execution and delivery to BSC of the Restated December 2009 Note, BSC shall surrender the December 2009 Note to the Company for cancellation. 

III. AMENDMENTS TO THE PATENT SECURITY AGREEMENT. 
 3.1 Amendment of Definition of “Loans”. The Company and BSC hereby agree that all references in the Patent Security Agreement to the Loans shall be deemed to refer to the Loans as
defined in the Loan Agreement as amended by this Amendment. 
 3.2 Amendment of Schedule A. The Company and BSC
hereby agree that Schedule A to the Patent Security Agreement is hereby amended and restated in its entirety to read as set forth on Schedule A hereto. 
 IV. CONDITIONS TO EFFECTIVENESS. 
 4.1 Conditions to
Effectiveness. The effectiveness of this Amendment is subject to the satisfaction of the following conditions precedent: 
 (a) the execution and delivery by the parties hereto of this Amendment; 

  
 4 

 (b) the execution and delivery by Boston Scientific Neuromodulation Corporation and the
Company of the IP Amendment; 
 (c) approval by the board of directors of the Company of the execution and delivery of this
Amendment and the IP Amendment by the Company; and 
 (d) the Company shall have received all consents and waivers necessary for
the consummation of the transactions contemplated by this Amendment and the IP Amendment, if any. 
 V. REPRESENTATIONS
AND WARRANTIES OF THE COMPANY AND CONFIRMATION OF SECURITY INTEREST. 
 5.1 Representations and Warranties.
Except as set forth in Schedule B hereto, the representations and warranties made by the Company in Section 4 of the Loan Agreement and in Section 3 of the Patent Security Agreement are true and correct in all material respects on
the date hereof with the same force and effect as if such representations and warranties had been made at and as of the date hereof. 
 5.2. No Material Breach. The Company is not in material breach of its obligations under the Loan Agreement, the Patent Security Agreement or the Existing Notes. 

5.3 Consents. There is no third party consent, approval or filing required for the execution and delivery by the Company of
this Amendment or the IP Amendment, except for any such consent, approval or filing already obtained or made by the Company and which is disclosed on Schedule B. 
 5.4 Confirmation of Security Interest. The Company hereby confirms the security interest granted by the Company to BSC pursuant to the Loan Agreement in the Collateral and the security
interest granted by the Company to BSC pursuant to the Patent Security Agreement in the Patent Collateral. The Company has not granted any lien, pledge, charge or security interest of any kind or nature in the Collateral or the Patent Collateral,
except to BSC and as set forth in Schedule B. 
 VI. MISCELLANEOUS. 

6.1. No Other Amendments. Except to the extent amended hereby, all of the definitions, terms, provisions and conditions set
forth in the Loan Agreement are hereby ratified and confirmed and shall remain in full force and effect. The Loan Agreement and this Amendment shall be read and construed together as a single agreement. 

6.2. Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Amendment shall inure to
the benefit of and be binding upon the 

  
 5 

 
respective successors and assigns of the parties. Nothing in this Amendment, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors
and assigns any rights, remedies, obligations, or liabilities under or by reason of this Amendment, except as expressly provided in this Amendment. 
 6.3. Governing Law. This Amendment shall for all purposes be construed in accordance with and governed by the laws of the Commonwealth of Massachusetts. 

6.4. Counterparts. This Amendment may be executed in two or more counterparts and the signatures delivered by facsimile,
each of which shall be deemed an original, with the same effect as if the signatures were upon the same instrument and delivered in person. 
 6.5. Severability. If one or more provisions of this Amendment are held to be unenforceable under applicable law, such provision shall be excluded from this Amendment and the balance of the
Amendment shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 

6.6 Assignment of Transferred Patents. The IP Amendment provides for the Company’s assignment to Boston Scientific
Neuromodulation Corporation of the “Transferred Patents” upon the occurrence of a “Triggering Event” (as such terms are defined in the IP Amendment). BSC acknowledges the provisions of the IP Amendment and hereby consents
pursuant to the Loan Agreement and the Patent Security Agreement to any such assignment to Boston Scientific Neuromodulation Corporation. 

  
 6 

 IN WITNESS WHEREOF, the
parties have caused this Amendment to be executed and delivered by their duly authorized representatives, all as of the day and year written above. 
  

			
	MRI INTERVENTIONS, INC.
		
	By:	 	 /s/ Kimble Jenkins

	Name: K. Jenkins
	Title: CEO
	
	BOSTON SCIENTIFIC CORPORATION
		
	By:	 	 /s/ Charles Attlan

	Name: Charles Attlan
	Title: VP Business Development

 Exhibit A 

Restated October 2009 Note 
 See Attached. 

 NEITHER THIS NOTE NOR ANY SECURITIES THAT MAY BE ISSUED UPON CONVERSION HEREOF HAVE BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR REGISTERED OR QUALIFIED UNDER ANY STATE SECURITIES LAWS. THIS NOTE AND ANY SUCH SECURITIES MAY NOT BE TRANSFERRED UNLESS SO REGISTERED AND QUALIFIED UNDER ALL APPLICABLE SECURITIES LAWS, OR UNLESS SUCH
REGISTRATION AND QUALIFICATION ARE NOT REQUIRED. 
 AMENDED AND RESTATED

 SECURED CONVERTIBLE PROMISSORY NOTE 

 

	 $2,492,931.51 
	 Dated: October 16, 2009 

 Restated: February 2, 2012 
 FOR VALUE RECEIVED, the undersigned,
MRI Interventions, Inc., a Delaware corporation formerly known as SurgiVision, Inc. (the “Company”), hereby promises to pay to Boston Scientific Corporation, or its assigns hereunder (“BSC”), prior to
or on the Maturity Date (as defined below) and subject to acceleration or conversion as set forth herein, the aggregate principal amount of TWO MILLION FOUR HUNDRED NINETY-TWO THOUSAND NINE HUNDRED THIRTY-ONE DOLLARS AND FIFTY-ONE CENTS
($2,492,931.51) (such initial amount, and any amounts added thereto in accordance with the terms hereof, being referred to as the “Principal Amount”). This Note shall bear interest at a rate equal to 0%; provided, however,
that any overdue amount payable hereunder shall bear interest compounded annually at a rate equal to 10% per annum from the date such payment was due until the date such amount shall be paid in full. Unless the indebtedness evidenced by this
Note becomes due and payable earlier as provided herein, the entire Principal Amount shall be payable in full by the Company on the Maturity Date. The obligations of the Company under this Note are secured by a pledge of the assets of the Company as
described in Section 5. 
 1. Defined Terms. This Note evidences borrowings under and has been issued by the Company in
accordance with the terms of that certain Loan Agreement, dated October 16, 2009, as amended, between the Company and BSC (the “Loan Agreement”). This Note amends, restates, replaces and supersedes, in all respects, the
Secured Convertible Promissory Note dated October 16, 2009, issued by the Company to BSC in the original principal amount of $2,000,000 pursuant to the Loan Agreement. As used herein, “BSC” shall also be deemed to refer to any
subsequent Holder of this Note. All capitalized terms used in this Note and not otherwise defined herein shall have the same meanings herein as in the Loan Agreement. BSC and any Holder hereof is entitled to the benefits of the Loan Agreement, and
may enforce the agreements of the Company contained therein, and any Holder hereof may exercise the respective remedies provided for thereby or otherwise available in respect thereof, all in accordance with the respective terms thereof. For
purposes of this Note, the terms listed below shall have the respective meanings set forth below: 
 1.1
“business day” means any day, other than Saturday, Sunday or a legal holiday that banks located in Boston, Massachusetts are not open for business; 
 1.2 “Holder” shall mean, initially, BSC and thereafter, any subsequent holder of this Note in accordance with the provisions of Section 7 below; and 

1.3 “Maturity Date” means October 16, 2014. 

	2.	Payment. 

 2.1
Payments. Payment of interest (if any) and principal hereunder shall be made as provided herein to the business address of the Holder. If the payments to be made by the Company shall be stated to be due on a date which is not a business
day, such payment may be made on the next succeeding business day, and any interest payment on each such date shall include the amount thereof which shall accrue during the period of such extension of time. All computations of interest payable under
this Note shall be made on the basis of the actual number of calendar days elapsed divided by 365. All payments hereunder shall be applied first to any unpaid accrued interest, and second to repayment of any unpaid principal amount hereunder.

 2.2 Prepayment. 
 (a) Optional Prepayment. The Company shall be permitted to prepay any unpaid portion of this Note at any time prior to the Maturity Date. 

(b) Mandatory Prepayment. The Company shall be required to prepay the unpaid portion of this Note out of the proceeds of any
Qualified Financing as provided in Section 3.3(b) of the Loan Agreement. 
 3. Conversion. This Note shall be convertible
into Conversion Shares in accordance with the terms and subject to the conditions set forth in the Loan Agreement. 
 4.
Acceleration. Upon the occurrence of any Event of Default (as defined below) and so long as any Event of Default is continuing, the Holder may, at its option and upon written notice of acceleration given by the Holder to the Company,
declare the entire unpaid portion of this Note due and payable. Each of the following events shall be deemed an “Event of Default”: (a) the Company shall fail to pay any portion of the Principal Amount or other
sums due hereunder within fifteen (15) days after the same shall become due and payable, whether at the stated date of maturity or any accelerated date of maturity or at any other date fixed for payment, (b) commencement of proceedings for
the liquidation or dissolution of the Company, or any other termination or winding-up of its existence or business, (c) appointment of any receiver, including a temporary receiver, for the Company or substantially all its assets,
(d) assignment of its assets by the Company for the benefit of its creditors, (e) material breach by the Company or any of its subsidiaries of any provision of this Note, the Patent Security Agreement or the Loan Agreement (other than any
breach covered by another clause of this Section 4), provided, that if such breach is capable of being cured, then such breach shall not constitute an “Event of Default” until the thirtieth (30th) day following notice thereof from the Holder, to the extent
such breach has not been cured prior to such date, (f) institution by or against the Company of insolvency, receivership or bankruptcy proceedings or any other similar proceedings for the settlement of the Company’s debts, provided,
that in the case of an involuntary proceeding commenced against the Company by a third party creditor whose claim against the Company is less than $100,000, such proceeding shall have remained undismissed and unstayed for more than thirty
(30) days, (g) an event of default under any mortgage, indenture, obligation, instrument or indebtedness of the Company for borrowed money, which default results in $100,000 or more (in the aggregate) of such indebtedness to become due and
payable by the Company prior to its stated maturity date, (h) any representation or warranty of the Company contained in the Loan Agreement or the Patent Security Agreement shall prove to have been false in any material respect when made or
deemed to have been made or repeated, provided, that if such breach is capable of being cured, then such breach shall not constitute an “Event of Default” until the thirtieth (30th) day following the date the Company becomes aware of the
factual circumstances giving rise to the breach, to the extent such breach has not been cured prior to such date, unless such breach has had a material impairment on BSC’s rights under the Notes, the Patent Security Agreement or the Loan
Agreement, (i) there shall remain in force, undischarged, unsatisfied, unvacated, unbonded or unstayed, for more than sixty (60) days, any final judgment against 

  
 2 

 
the Company or any of its subsidiaries that, with other such outstanding final judgments against the Company or any of its subsidiaries that are undischarged, unsatisfied, unvacated, unbonded or
unstayed, exceeds in the aggregate $500,000 in excess of insurance coverage, (j) this Note shall be cancelled, terminated, revoked or rescinded, or any action at law, suit or in equity or other legal proceeding to cancel, revoke or rescind this
Note shall be commenced by or on behalf of the Company or any of its subsidiaries party thereto or any of their respective shareholders, or any court or any other governmental or regulatory authority or agency of competent jurisdiction shall make a
determination that, or issue a judgment, order, decree or ruling to the effect that, this Note is illegal, invalid or unenforceable in accordance with the terms thereof, (k) breach by the Company of Section 11.7(e) of the System and Lead
Development and Transfer Agreement dated as of December 30, 2005, as amended and in effect from time to time, or (l) breach by the Company of Section 6.8 of the Loan Agreement. At BSC’s option, the entire unpaid portion of this
Note will become due and payable upon written notice of acceleration given by BSC to the Company at any time upon or after consummation of a Sale of the Company. 
 5. Security Interest. This Note is secured by a first priority security interest in all of the Company’s property and assets pursuant to the Loan Agreement, to which reference is made
for a description of the security for this Note. 
 6. Independent Obligations. The Company agrees and acknowledges that each
covenant contained in Sections 3 and 5 hereof constitutes an independent obligation of the Company, not qualified by any other clause, and shall be deemed to be cumulative. 
 7. Assignment. This Note shall not be assigned by operation of law or otherwise, except that the Holder may assign this Note to any assignee of BSC’s rights and obligation under the
Loan Agreement. 
 8. Waiver of Presentment, Etc. Except as otherwise set forth herein, the Company hereby, to the fullest extent
permitted by applicable law, waives presentment, demand, notice, protest, and all other demands and notices in connection with delivery, acceptance, performance, default, acceleration or enforcement of or under this Note. 

9. Amendment; Waivers. Neither this Note nor any term hereof may be waived, amended, discharged, modified, changed, or terminated orally,
nor shall any waiver of any provision hereof be effective except by an instrument in writing signed by the party granting the waiver. The failure of the Holder hereof to exercise any of its rights, remedies, powers or privileges hereunder in any
instance will not constitute a waiver thereof, or of any other right or remedy, and no single or partial exercise of any right or remedy shall preclude any other or further exercise thereof or of any other right or remedy. 

10. Payment of Collection Costs. The Company will pay on demand all costs of collection, including all court costs and reasonable
attorneys’ fees, paid or incurred by the Holder in enforcing this Note after default. 
 11. GOVERNING LAW. THIS NOTE WILL BE
GOVERNED BY AND INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE COMMONWEALTH OF MASSACHUSETTS (WITHOUT REFERENCE TO PRINCIPLES OF CHOICE OF LAW). 
 [The remainder of this page is intentionally left blank.] 

  
 3 

 IN WITNESS WHEREOF, the
Company has executed and delivered this Amended and Restated Secured Convertible Promissory Note as an instrument as of the date first above written. 

 

			
	MRI INTERVENTIONS, INC.
		
	BY	 	  

	Name:	 	
	Title:	 	

 Exhibit B 

Restated November 2009 Note 
 See Attached. 

 NEITHER THIS NOTE NOR ANY SECURITIES THAT MAY BE ISSUED UPON CONVERSION HEREOF HAVE BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR REGISTERED OR QUALIFIED UNDER ANY STATE SECURITIES LAWS. THIS NOTE AND ANY SUCH SECURITIES MAY NOT BE TRANSFERRED UNLESS SO REGISTERED AND QUALIFIED UNDER ALL APPLICABLE SECURITIES LAWS, OR UNLESS SUCH
REGISTRATION AND QUALIFICATION ARE NOT REQUIRED. 
 AMENDED AND RESTATED

 SECURED CONVERTIBLE PROMISSORY NOTE 

 

			
	$926,893.15	  	 Dated: November 17, 2009
 Restated: February 2, 2012

 FOR VALUE RECEIVED, the undersigned, MRI Interventions, Inc., a Delaware corporation formerly
known as SurgiVision, Inc. (the “Company”), hereby promises to pay to Boston Scientific Corporation, or its assigns hereunder (“BSC”), prior to or on the Maturity Date (as defined below) and subject to
acceleration or conversion as set forth herein, the aggregate principal amount of NINE HUNDRED TWENTY-SIX THOUSAND EIGHT HUNDRED NINETY-THREE DOLLARS AND FIFTEEN CENTS ($926,893.15) (such initial amount, and any amounts added thereto in accordance
with the terms hereof, being referred to as the “Principal Amount”). This Note shall bear interest at a rate equal to 0%; provided, however, that any overdue amount payable hereunder shall bear interest compounded annually at
a rate equal to 10% per annum from the date such payment was due until the date such amount shall be paid in full. Unless the indebtedness evidenced by this Note becomes due and payable earlier as provided herein, the entire Principal Amount
shall be payable in full by the Company on the Maturity Date. The obligations of the Company under this Note are secured by a pledge of the assets of the Company as described in Section 5. 

12. Defined Terms. This Note evidences borrowings under and has been issued by the Company in accordance with the terms of that certain
Loan Agreement, dated October 16, 2009, as amended, between the Company and BSC (the “Loan Agreement”). This Note amends, restates, replaces and supersedes, in all respects, the Secured Convertible Promissory Note dated
November 17, 2009, issued by the Company to BSC in the original principal amount of $750,000 pursuant to the Loan Agreement. As used herein, “BSC” shall also be deemed to refer to any subsequent Holder of this Note. All capitalized
terms used in this Note and not otherwise defined herein shall have the same meanings herein as in the Loan Agreement. BSC and any Holder hereof is entitled to the benefits of the Loan Agreement, and may enforce the agreements of the Company
contained therein, and any Holder hereof may exercise the respective remedies provided for thereby or otherwise available in respect thereof, all in accordance with the respective terms thereof. For purposes of this Note, the terms listed
below shall have the respective meanings set forth below: 
 12.1 “business day” means any day, other
than Saturday, Sunday or a legal holiday that banks located in Boston, Massachusetts are not open for business; 
 12.2
“Holder” shall mean, initially, BSC and thereafter, any subsequent holder of this Note in accordance with the provisions of Section 7 below; and 
 12.3 “Maturity Date” means November 17, 2014. 

 13. Payment. 
 13.1 Payments. Payment of interest (if any) and principal hereunder shall be made as provided herein to the business address of the Holder. If the payments to be made by the Company shall be
stated to be due on a date which is not a business day, such payment may be made on the next succeeding business day, and any interest payment on each such date shall include the amount thereof which shall accrue during the period of such extension
of time. All computations of interest payable under this Note shall be made on the basis of the actual number of calendar days elapsed divided by 365. All payments hereunder shall be applied first to any unpaid accrued interest, and second to
repayment of any unpaid principal amount hereunder. 
 13.2 Prepayment. 

(a) Optional Prepayment. The Company shall be permitted to prepay any unpaid portion of this Note at any time prior to the Maturity
Date. 
 (b) Mandatory Prepayment. The Company shall be required to prepay the unpaid portion of this Note out of the
proceeds of any Qualified Financing as provided in Section 3.3(b) of the Loan Agreement. 
 14. Conversion. This Note shall
be convertible into Conversion Shares in accordance with the terms and subject to the conditions set forth in the Loan Agreement. 
 15. Acceleration. Upon the occurrence of any Event of Default (as defined below) and so long as any Event of Default is continuing, the Holder may, at its option and upon written notice of
acceleration given by the Holder to the Company, declare the entire unpaid portion of this Note due and payable. Each of the following events shall be deemed an “Event of Default”: (a) the Company shall fail to
pay any portion of the Principal Amount or other sums due hereunder, within fifteen (15) days after the same shall become due and payable, whether at the stated date of maturity or any accelerated date of maturity or at any other date fixed for
payment, (b) commencement of proceedings for the liquidation or dissolution of the Company, or any other termination or winding-up of its existence or business, (c) appointment of any receiver, including a temporary receiver, for the
Company or substantially all its assets, (d) assignment of its assets by the Company for the benefit of its creditors, (e) material breach by the Company or any of its subsidiaries of any provision of this Note, the Patent Security
Agreement or the Loan Agreement (other than any breach covered by another clause of this Section 4), provided, that if such breach is capable of being cured, then such breach shall not constitute an “Event of Default” until the
thirtieth (30th) day following notice thereof from
the Holder, to the extent such breach has not been cured prior to such date, (f) institution by or against the Company of insolvency, receivership or bankruptcy proceedings or any other similar proceedings for the settlement of the
Company’s debts, provided, that in the case of an involuntary proceeding commenced against the Company by a third party creditor whose claim against the Company is less than $100,000, such proceeding shall have remained undismissed and
unstayed for more than thirty (30) days, (g) an event of default under any mortgage, indenture, obligation, instrument or indebtedness of the Company for borrowed money, which default results in $100,000 or more (in the aggregate) of such
indebtedness to become due and payable by the Company prior to its stated maturity date, (h) any representation or warranty of the Company contained in the Loan Agreement or the Patent Security Agreement shall prove to have been false in any
material respect when made or deemed to have been made or repeated, provided, that if such breach is capable of being cured, then such breach shall not constitute an “Event of Default” until the thirtieth (30th) day following the date the Company becomes aware of the
factual circumstances giving rise to the breach, to the extent such breach has not been cured prior to such date, unless such breach has had a material impairment on BSC’s rights under the Notes, the Patent Security Agreement or the Loan
Agreement, (i) there shall remain in force, undischarged, unsatisfied, unvacated, unbonded or unstayed, for more than sixty (60) days, any final judgment against 

  
 2 

 
the Company or any of its subsidiaries that, with other such outstanding final judgments against the Company or any of its subsidiaries that are undischarged, unsatisfied, unvacated, unbonded or
unstayed, exceeds in the aggregate $500,000 in excess of insurance coverage, (j) this Note shall be cancelled, terminated, revoked or rescinded, or any action at law, suit or in equity or other legal proceeding to cancel, revoke or rescind this
Note shall be commenced by or on behalf of the Company or any of its subsidiaries party thereto or any of their respective shareholders, or any court or any other governmental or regulatory authority or agency of competent jurisdiction shall make a
determination that, or issue a judgment, order, decree or ruling to the effect that, this Note is illegal, invalid or unenforceable in accordance with the terms thereof, (k) breach by the Company of Section 11.7(e) of the System and Lead
Development and Transfer Agreement dated as of December 30, 2005, as amended and in effect from time to time, or (l) breach by the Company of Section 6.8 of the Loan Agreement. At BSC’s option, the entire unpaid portion of this
Note will become due and payable upon written notice of acceleration given by BSC to the Company at any time upon or after consummation of a Sale of the Company. 
 16. Security Interest. This Note is secured by a first priority security interest in all of the Company’s property and assets pursuant to the Loan Agreement, to which reference is made
for a description of the security for this Note. 
 17. Independent Obligations. The Company agrees and acknowledges that each
covenant contained in Sections 3 and 5 hereof constitutes an independent obligation of the Company, not qualified by any other clause, and shall be deemed to be cumulative. 
 18. Assignment. This Note shall not be assigned by operation of law or otherwise, except that the Holder may assign this Note to any assignee of BSC’s rights and obligation under the
Loan Agreement. 
 19. Waiver of Presentment, Etc. Except as otherwise set forth herein, the Company hereby, to the fullest extent
permitted by applicable law, waives presentment, demand, notice, protest, and all other demands and notices in connection with delivery, acceptance, performance, default, acceleration or enforcement of or under this Note. 

20. Amendment; Waivers. Neither this Note nor any term hereof may be waived, amended, discharged, modified, changed, or terminated orally,
nor shall any waiver of any provision hereof be effective except by an instrument in writing signed by the party granting the waiver. The failure of the Holder hereof to exercise any of its rights, remedies, powers or privileges hereunder in any
instance will not constitute a waiver thereof, or of any other right or remedy, and no single or partial exercise of any right or remedy shall preclude any other or further exercise thereof or of any other right or remedy. 

21. Payment of Collection Costs. The Company will pay on demand all costs of collection, including all court costs and reasonable
attorneys’ fees, paid or incurred by the Holder in enforcing this Note after default. 
 22. GOVERNING LAW. THIS NOTE WILL BE
GOVERNED BY AND INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE COMMONWEALTH OF MASSACHUSETTS (WITHOUT REFERENCE TO PRINCIPLES OF CHOICE OF LAW). 
 [The remainder of this page is intentionally left blank.] 

  
 3 

 IN WITNESS WHEREOF, the
Company has executed and delivered this Amended and Restated Secured Convertible Promissory Note as an instrument as of the date first above written. 

 

			
	MRI INTERVENTIONS, INC.
		
	By	 	  

	Name:
	Title:

 Exhibit C 

Restated December 2009 Note 
 See Attached. 

 NEITHER THIS NOTE NOR ANY SECURITIES THAT MAY BE ISSUED UPON CONVERSION HEREOF HAVE BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR REGISTERED OR QUALIFIED UNDER ANY STATE SECURITIES LAWS. THIS NOTE AND ANY SUCH SECURITIES MAY NOT BE TRANSFERRED UNLESS SO REGISTERED AND QUALIFIED UNDER ALL APPLICABLE SECURITIES LAWS, OR UNLESS SUCH
REGISTRATION AND QUALIFICATION ARE NOT REQUIRED. 
 AMENDED AND RESTATED

 SECURED CONVERTIBLE PROMISSORY NOTE 

 

			
	$918,776.58	  	 Dated: December 18,2009
 Restated:February 2,2012

 FOR VALUE RECEIVED, the undersigned, MRI Interventions, Inc., a Delaware corporation formerly
known as SurgiVision, Inc. (the “Company”), hereby promises to pay to Boston Scientific Corporation, or its assigns hereunder (“BSC”), prior to or on the Maturity Date (as defined below) and subject to
acceleration or conversion as set forth herein, the aggregate principal amount of NINE HUNDRED EIGHTEEN THOUSAND SEVEN HUNDRED SEVENTY-SIX DOLLARS AND FIFTY-EIGHT CENTS ($918,776.58) (such initial amount, and any amounts added thereto in accordance
with the terms hereof, being referred to as the “Principal Amount”). This Note shall bear interest at a rate equal to 0%; provided, however, that any overdue amount payable hereunder shall bear interest compounded annually at
a rate equal to 10% per annum from the date such payment was due until the date such amount shall be paid in full. Unless the indebtedness evidenced by this Note becomes due and payable earlier as provided herein, the entire Principal Amount
shall be payable in full by the Company on the Maturity Date. The obligations of the Company under this Note are secured by a pledge of the assets of the Company as described in Section 5. 

23. Defined Terms. This Note evidences borrowings under and has been issued by the Company in accordance with the terms of that certain
Loan Agreement, dated October 16, 2009, as amended, between the Company and BSC (the “Loan Agreement”). This Note amends, restates, replaces and supersedes, in all respects, the Secured Convertible Promissory Note dated
December 18, 2009, issued by the Company to BSC in the original principal amount of $750,000 pursuant to the Loan Agreement. As used herein, “BSC” shall also be deemed to refer to any subsequent Holder of this Note. All capitalized
terms used in this Note and not otherwise defined herein shall have the same meanings herein as in the Loan Agreement. BSC and any Holder hereof is entitled to the benefits of the Loan Agreement, and may enforce the agreements of the Company
contained therein, and any Holder hereof may exercise the respective remedies provided for thereby or otherwise available in respect thereof, all in accordance with the respective terms thereof. For purposes of this Note, the terms listed
below shall have the respective meanings set forth below: 
 23.1 “business day” means any day, other
than Saturday, Sunday or a legal holiday that banks located in Boston, Massachusetts are not open for business; 
 23.2
“Holder” shall mean, initially, BSC and thereafter, any subsequent holder of this Note in accordance with the provisions of Section 7 below; and 
 23.3 “Maturity Date” means December 18, 2014. 

 24. Payment. 
 24.1 Payments. Payment of interest (if any) and principal hereunder shall be made as provided herein to the business address of the Holder. If the payments to be made by the Company shall be
stated to be due on a date which is not a business day, such payment may be made on the next succeeding business day, and any interest payment on each such date shall include the amount thereof which shall accrue during the period of such extension
of time. All computations of interest payable under this Note shall be made on the basis of the actual number of calendar days elapsed divided by 365. All payments hereunder shall be applied first to any unpaid accrued interest, and second to
repayment of any unpaid principal amount hereunder. 
 24.2 Prepayment. 

(a) Optional Prepayment. The Company shall be permitted to prepay any unpaid portion of this Note at any time prior to the Maturity
Date. 
 (b) Mandatory Prepayment. The Company shall be required to prepay the unpaid portion of this Note out of the
proceeds of any Qualified Financing as provided in Section 3.3(b) of the Loan Agreement. 
 25. Conversion. This Note shall
be convertible into Conversion Shares in accordance with the terms and subject to the conditions set forth in the Loan Agreement. 
 26. Acceleration. Upon the occurrence of any Event of Default (as defined below) and so long as any Event of Default is continuing, the Holder may, at its option and upon written notice of
acceleration given by the Holder to the Company, declare the entire unpaid portion of this Note due and payable. Each of the following events shall be deemed an “Event of Default”: (a) the Company shall fail to
pay any portion of the Principal Amount or other sums due hereunder, within fifteen (15) days after the same shall become due and payable, whether at the stated date of maturity or any accelerated date of maturity or at any other date fixed for
payment, (b) commencement of proceedings for the liquidation or dissolution of the Company, or any other termination or winding-up of its existence or business, (c) appointment of any receiver, including a temporary receiver, for the
Company or substantially all its assets, (d) assignment of its assets by the Company for the benefit of its creditors, (e) material breach by the Company or any of its subsidiaries of any provision of this Note, the Patent Security
Agreement or the Loan Agreement (other than any breach covered by another clause of this Section 4), provided, that if such breach is capable of being cured, then such breach shall not constitute an “Event of Default” until the
thirtieth (30th) day following notice thereof from
the Holder, to the extent such breach has not been cured prior to such date, (f) institution by or against the Company of insolvency, receivership or bankruptcy proceedings or any other similar proceedings for the settlement of the
Company’s debts, provided, that in the case of an involuntary proceeding commenced against the Company by a third party creditor whose claim against the Company is less than $100,000, such proceeding shall have remained undismissed and
unstayed for more than thirty (30) days, (g) an event of default under any mortgage, indenture, obligation, instrument or indebtedness of the Company for borrowed money, which default results in $100,000 or more (in the aggregate) of such
indebtedness to become due and payable by the Company prior to its stated maturity date, (h) any representation or warranty of the Company contained in the Loan Agreement or the Patent Security Agreement shall prove to have been false in any
material respect when made or deemed to have been made or repeated, provided, that if such breach is capable of being cured, then such breach shall not constitute an “Event of Default” until the thirtieth (30th) day following the date the Company becomes aware of the
factual circumstances giving rise to the breach, to the extent such breach has not been cured prior to such date, unless such breach has had a material impairment on BSC’s rights under the Notes, the Patent Security Agreement or the Loan
Agreement, (i) there shall remain in force, undischarged, unsatisfied, unvacated, unbonded or unstayed, for more than sixty (60) days, any final judgment against 

  
 2 

 
the Company or any of its subsidiaries that, with other such outstanding final judgments against the Company or any of its subsidiaries that are undischarged, unsatisfied, unvacated, unbonded or
unstayed, exceeds in the aggregate $500,000 in excess of insurance coverage, (j) this Note shall be cancelled, terminated, revoked or rescinded, or any action at law, suit or in equity or other legal proceeding to cancel, revoke or rescind this
Note shall be commenced by or on behalf of the Company or any of its subsidiaries party thereto or any of their respective shareholders, or any court or any other governmental or regulatory authority or agency of competent jurisdiction shall make a
determination that, or issue a judgment, order, decree or ruling to the effect that, this Note is illegal, invalid or unenforceable in accordance with the terms thereof, (k) breach by the Company of Section 11.7(e)) of the System and Lead
Development and Transfer Agreement dated as of December 30, 2005, as amended and in effect from time to time, or (l) breach by the Company of Section 6.8 of the Loan Agreement. At BSC’s option, the entire unpaid portion of this
Note will become due and payable upon written notice of acceleration given by BSC to the Company at any time upon or after consummation of a Sale of the Company. 
 27. Security Interest. This Note is secured by a first priority security interest in all of the Company’s property and assets pursuant to the Loan Agreement, to which reference is made
for a description of the security for this Note. 
 28. Independent Obligations. The Company agrees and acknowledges that each
covenant contained in Sections 3 and 5 hereof constitutes an independent obligation of the Company, not qualified by any other clause, and shall be deemed to be cumulative. 
 29. Assignment. This Note shall not be assigned by operation of law or otherwise, except that the Holder may assign this Note to any assignee of BSC’s rights and obligation under the
Loan Agreement. 
 30. Waiver of Presentment, Etc. Except as otherwise set forth herein, the Company hereby, to the fullest extent
permitted by applicable law, waives presentment, demand, notice, protest, and all other demands and notices in connection with delivery, acceptance, performance, default, acceleration or enforcement of or under this Note. 

31. Amendment; Waivers. Neither this Note nor any term hereof may be waived, amended, discharged, modified, changed, or terminated orally,
nor shall any waiver of any provision hereof be effective except by an instrument in writing signed by the party granting the waiver. The failure of the Holder hereof to exercise any of its rights, remedies, powers or privileges hereunder in any
instance will not constitute a waiver thereof, or of any other right or remedy, and no single or partial exercise of any right or remedy shall preclude any other or further exercise thereof or of any other right or remedy. 

32. Payment of Collection Costs. The Company will pay on demand all costs of collection, including all court costs and reasonable
attorneys’ fees, paid or incurred by the Holder in enforcing this Note after default. 
 33. GOVERNING LAW. THIS NOTE WILL BE
GOVERNED BY AND INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE COMMONWEALTH OF MASSACHUSETTS (WITHOUT REFERENCE TO PRINCIPLES OF CHOICE OF LAW). 
 [The remainder of this page is intentionally left blank.] 

  
 3 

 IN WITNESS WHEREOF, the
Company has executed and delivered this Amended and Restated Secured Convertible Promissory Note as an instrument as of the date first above written. 

 

			
	MRI INTERVENTIONS, INC.
		
	BY	 	  

	Name:
	Title:

 Schedule A 

See Attached 

 Schedule A 

ISSUED AND PENDING PATENTS 
 Patents Issued by U.S. Patent 
 and Trademark Office

 [***] 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request
for confidential treatment. 

 Schedule A 

ISSUED AND PENDING PATENTS 
 Patents Issued by Foreign Offices 
 [***] 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request
for confidential treatment. 

 Schedule A 

ISSUED AND PENDING PATENTS 
 Patents Issued by Foreign Offices 
 [***] 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request
for confidential treatment. 

 Schedule A 

ISSUED AND PENDING PATENTS 
 Patents Pending with U.S. Patent 
 and Trademark Office

 [***] 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request
for confidential treatment. 

 Schedule A 

ISSUED AND PENDING PATENTS 
 Patents Pending with U.S. Patent 
 and Trademark Office

 [***] 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request
for confidential treatment. 

 Schedule A 

ISSUED AND PENDING PATENTS 
 Patents Pending with Foreign Offices 
 [***] 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request
for confidential treatment. 

 Schedule A 

ISSUED AND PENDING PATENTS 
 Patents Pending with Foreign Offices 
 [***] 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request
for confidential treatment. 

 Schedule A 

ISSUED AND PENDING PATENTS 
 Patents Pending with Foreign Offices 
 [***] 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request
for confidential treatment. 

 Schedule A 

ISSUED AND PENDING PATENTS 
 Patents Pending with Foreign Offices 
 [***] 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request
for confidential treatment. 

 Schedule A 

ISSUED AND PENDING PATENTS 
 Patents Pending with Foreign Offices 
 [***] 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request
for confidential treatment. 

 Schedule B 

Exceptions to Representations and Warranties 
  

	4.1	Organization, Good Standing and Qualification 

  

	(b)	The Company does not have any Subsidiaries. Cardiac EP, Sub, Inc. was merged with and into the Company on June 11, 2010. 

 

	4.2	Capitalization 

  

	(a)	The authorized capital stock of the Company consists of: (i) 30,000,000 shares of Preferred Stock, of which 8,000,000 shares have been designated Series A
Preferred Stock and of which 7,965,000 shares of Series A Preferred Stock are issued and outstanding; and (ii) 70,000,000 shares of Common Stock of which 16,084,981 shares are issued and outstanding. 

 

	(b)	There are presently 287,500 shares of Common Stock subject to outstanding options awarded under the Company’s 1998 Stock Option Plan. 

There are presently 129,875 shares of Common Stock subject to outstanding options awarded under the Company’s 2007 Stock Incentive
Plan. 
 There are presently 824,950 shares of Common Stock subject to outstanding options awarded under the Company’s 2010
Incentive Compensation Plan. 
 There are presently 2,371,000 shares of Common Stock subject to outstanding options awarded under
the Company’s 2010 Non-Qualified Stock Option Plan. 
 There are presently 1,989,596 shares of Common Stock subject to
outstanding warrants issued by the Company. 
 As provided in the Company’s Amended and Restated Certificate of
Incorporation, shares of Series A Preferred Stock are convertible into shares of Common Stock. 
 In March 2010, the Company
issued 10% Senior Unsecured Convertible Notes in the aggregate principal amount of $4,071,000, which notes are convertible into shares of Common Stock. 
 In April 2011, the Company issued to Brainlab AG the 10% Subordinated Secured Convertible Note in the aggregate principal amount of $2,000,000, which note is convertible into shares of the Company’s
capital stock. 

 In June through September 2011, the Company issued Unsecured Convertible Promissory Notes in
the aggregate principal amount of $1,310,000, which notes are convertible into shares of Common Stock. 
 In October 2011, the
Company commenced a private placement of its securities in which it is offering units, with each unit consisting of a 10% Secured Convertible Promissory Note in the principal amount of $100,000 and a warrant to purchase 50,000 shares of Common Stock
(the “Unit Offering”). The notes are convertible into shares of Common Stock. The Company is seeking to raise up to the aggregate amount of $6 million in the Unit Offering. 

Investors in the Unit Offering will receive limited participation rights with respect to the issuance of new securities by the Company.
While each investor’s note remains outstanding, such investor will have the pro rata right, based on its percentage equity ownership in the Company (assuming the conversion of the note into shares of Common Stock and the exercise of the
investor’s warrant for shares of Common Stock) to participate in subsequent issuances of equity securities by the Company. This participation right will terminate upon payment or conversion of the note. In addition, this participation right
will not apply with respect to: (i) securities issued pursuant to the Company’s acquisition of another company, regardless of the form of the transaction; (ii) securities issued upon exercise or conversion of any options, warrants,
notes or other convertible securities; (iii) securities (including, but not limited to, options) granted or issued to the Company’s employees, officers, directors, consultants or advisors pursuant to plans or agreements approved by the
Board of Directors or a duly authorized committee of the Board of Directors; (iv) securities issued in a public offering pursuant to an effective registration statement under the Securities Act; (v) securities issued in connection with
sponsored research, collaboration, technology license, development, OEM, distribution, marketing or other similar agreements or strategic partnerships approved by the Board of Directors or a duly authorized committee of the Board of Directors; or
(vi) securities issued with the consent of the holders of a majority in aggregate outstanding principal amount of the notes. 
  

	(d)	The Series A Preferred Stock is presently convertible into Common Stock on a one-for-four basis. The Company’s Board of Directors has approved an amendment to the
Certificate of Designation, Preferences, and Rights for the Series A Preferred Stock, in the form provided to BSC, that provides for the automatic conversion of the Series A Preferred Stock into Common Stock upon the effective date of a Form 10 or
other registration statement pursuant to which the Common Stock is registered as a class of securities under the Securities Exchange Act of 1934. With respect only to that specific conversion event, the Series A Preferred Stock will be convertible
into Common Stock on a one-for-one basis. 

  
 2 

	4.7	Outstanding Debt 

 In
March 2010, the Company issued 10% Senior Unsecured Convertible Notes in the aggregate principal amount of $4,071,000 (the “March 2010 Notes”). The March 2010 Notes are unsecured. If the March 2010 Notes are not amended or converted
into shares of Common Stock pursuant to Section 6.8 of the Loan Agreement, an Event of Default under the Restated Notes to BSC shall occur. 
 In November 2010, the Company issued Junior Secured Promissory Notes in the aggregate principal amount of $3,000,000 (the “November 2010 Notes”). The November 2010 Notes are subordinated
to the Restated Notes to BSC and are secured by a junior security interest in the Company’s assets. 
 In April 2011, the
Company issued to Brainlab AG a 10% Subordinated Secured Convertible Note in the aggregate principal amount of $2,000,000 (the “Brainlab Note”). The Brainlab Note is subordinated to the Restated Notes to BSC and is secured by a
junior security interest in the Company’s assets. If the Brainlab Note is not amended or converted into shares of Common Stock or Preferred Stock pursuant to Section 6.8 of the Loan Agreement, an Event of Default under the Restated Notes
to BSC shall occur. 
 In June through September 2011, the Company issued Unsecured Convertible Promissory Notes in the aggregate
principal amount of $1,310,000 (the “Summer 2011 Notes”). The Summer 2011 Notes are unsecured. If the Summer 2011 Notes are not amended or converted into shares of Common Stock pursuant to Section 6.8 of the Loan Agreement, an
Event of Default under the Restated Notes to BSC shall occur. 
 The Company commenced its Unit Offering in October 2011, in
which the Company is offering units that consist, in part, of a 10% Secured Convertible Promissory Note in the principal amount of $100,000, and collectively up to $6,000,000 in aggregate amount (the “Unit Offering Notes”). The Unit
Offering Notes are subordinated to the Restated Notes to BSC and are secured by a junior security interest in the Company’s assets. If the Unit Offering Notes are not amended or converted into shares of Common Stock pursuant to Section 6.8
of the Loan Agreement, an Event of Default under the Restated Notes to BSC shall occur. 

  
 3 

 Schedule 6.2 

Permitted Indebtedness 
 The March 2010 Notes. The March 2010 Notes are unsecured. If the March 2010 Notes are not amended or converted into shares of Common Stock pursuant to Section 6.8 of the Loan Agreement, an Event of
Default under the Restated Notes to BSC shall occur. 
 The November 2010 Notes. The November 2010 Notes are subordinated to the
Restated Notes to BSC and are secured by a junior security interest in the Company’s assets. 
 The Brainlab Note. The
Brainlab Note is subordinated to the Restated Notes to BSC and is secured by a junior security interest in the Company’s assets. If the Brainlab Note is not amended or converted into shares of Common Stock or Preferred Stock pursuant to
Section 6.8 of the Loan Agreement, an Event of Default under the Restated Notes to BSC shall occur. 
 The Summer 2011
Notes. The Summer 2011 Notes are unsecured. If the Summer 2011 Notes are not amended or converted into shares of Common Stock pursuant to Section 6.8 of the Loan Agreement, an Event of Default under the Restated Notes to BSC shall occur.

 The Unit Offering Notes. The Unit Offering Notes are subordinated to the Restated Notes to BSC and are secured by a junior
security interest in the Company’s assets. If the Unit Offering Notes are not amended or converted into shares of Common Stock pursuant to Section 6.8 of the Loan Agreement, an Event of Default under the Restated Notes to BSC shall occur.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}]]